~~United States~~UNITED ~~Securities and Exchange Commission~~STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

~~Form~~ FORM 10-K

~~☒ANNUAL REPORT UNDER SECTION 13 OR 15~~(d)Mark ~~OF THE SECURITIES EXCHANGE ACT OF 1934:~~ One)

For the fiscal year ending August 31, 2018

x	ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the fiscal year ended August 31, 2019

¨	TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ____________ to ____________

Commission file number 333-154989

~~☐ TRANSITION~~ENTEST ~~REPORT~~GROUP, ~~UNDER~~INC. ~~SECTION 13 OR 15~~(d)Exact OFname ~~THE~~of ~~SECURITIES~~registrant ~~EXCHANGE~~as ~~ACT~~specified OFin ~~1934:~~its ~~For the transition period from ___________ to ___________.~~charter)

Commission file number: 333-154989

Nevada		26-3431263
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

No. 911 Bao’an Book City Xinqiao Street Central Road, Bao’an District, Shenzhen, China
(Address of principal executive offices)		(Zip Code)

~~ENTEST GROUP~~Registrant’s telephone number, ~~INC.~~including area code: 86-13709631109

~~(Name of~~Securities ~~small~~registered ~~business~~pursuant ~~issuer~~to inSection ~~its charter~~12(b) of the Act:

Nevada		26-3431263
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
None	None	None

~~4700 Spring~~Securities ~~Street,~~registered ~~Suite~~pursuant ~~304,~~to LaSection ~~Mesa,~~12(g) ~~California,~~of ~~91942~~the Act:

N/A (~~Address~~ Title of ~~Principal executive offices~~class)

~~Issuer’s telephone~~Indicate ~~number:~~by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 the Securities Act. Yes ¨ No x Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) ~~619~~of the Act. Yes ¨ No x Indicate by check mark whether the registrant (1) ~~702~~has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the last 90 days. Yes x No ¨ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-~~1404~~ T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes x No ¨ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

~~_______________~~Large accelerated filer ¨ Accelerated filer ¨ Non-accelerated filer x Smaller reporting company x Emerging Growth Company ¨

~~Securities registered~~If ~~under~~an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 1213(ba) of the “Exchange Act”. ~~None~~¨ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes x No ¨ The aggregate market value of Common Stock held by non-affiliates of the Registrant on February 28, 2019, was $440,393 based on a $0.0192 average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter. Indicate the number of shares outstanding of each of the registrant’s classes of common stock as of the latest practicable date. 49,171,083 shares of common stock issued and outstanding as of December 16, 2019.

~~Securities registered~~TABLE ~~under~~OF ~~Section 12(g) of the Exchange Act: None~~CONTENTS

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

PART I		3
ITEM 1.	BUSINESS	3
ITEM 1A.	RISK FACTORS	4
ITEM 1B.	UNRESOLVED STAFF COMMENTS	4
ITEM 2.	PROPERTIES	4
ITEM 3.	LEGAL PROCEEDINGS	4
ITEM 4.	MINE SAFETY DISCLOSURES	4
PART II		5
ITEM 5.	MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES	5
ITEM 6.	SELECTED FINANCIAL DATA	5
ITEM 7.	MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS	6
ITEM 7A.	QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK	8
ITEM 8.	FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA	F-1
ITEM 9.	CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE	9
ITEM 9A.	CONTROLS AND PROCEDURES	9
ITEM 9B.	OTHER INFORMATION	10
PART III		11
ITEM 10.	DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE	11
ITEM 11.	EXECUTIVE COMPENSATION	13
ITEM 12.	SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS	15
ITEM 13.	CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE	17
ITEM 14.	PRINCIPAL ACCOUNTING FEES AND SERVICES	18
PART IV		19
ITEM 15.	EXHIBITS, FINANCIAL STATEMENT SCHEDULES	19
ITEM 16.	FORM 10-K SUMMARY	19
SIGNATURES		20

Yes ☒ No ☐

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K (§ 229.405 of this chapter) is not contained herein, and will not be contained, to the best of registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or smaller reporting company.

Large accelerated filer ☐ Accelerated filer ☐ Non accelerated filer ☐ Smaller reporting Company ☒

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).

Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Yes ☐ No☐

State the aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, as of the last business day of the registrant’s most recently completed second fiscal quarter: $ 470,842

As of November 16, 2018 Entest BioMedical, Inc. had 49,170,472 common shares outstanding, 728, 009 Series B Preferred shares outstanding , 667 Series AA preferred shares outstanding , 534 Series AAA preferred shares outstanding and 1001533 shares outstanding of the Company’s Non Voting Convertible Preferred Stock. .

In this annual report, the terms “Entest BioMedical, Inc.. ”, “Entest”, “Company”, “we”, or “our”, unless the context otherwise requires, mean Entest BioMedical, Inc., a Nevada corporation, and its subsidiaries.

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS

This annual report on Form 10-K and other reports that we file with the SEC contain statements that are considered forward-looking statements. Forward-looking statements give the Company’s current expectations, plans, objectives, assumptions or forecasts of future events. All statements other than statements of current or historical fact contained in this annual report, including statements regarding the Company’s future financial position, business strategy, budgets, projected costs and plans and objectives of management for future operations, are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “anticipate,” “estimate,” “plans,” “potential,” “projects,” “ongoing,” “expects,” “management believes,” “we believe,” “we intend,” and similar expressions. These statements are based on the Company’s current plans and are subject to risks and uncertainties, and as such the Company’s actual future activities and results of operations may be materially different from those set forth in the forward looking statements. Any or all of the forward-looking statements in this annual report may turn out to be inaccurate and as such, you should not place undue reliance on these forward-looking statements. The Company has based these forward-looking statements largely on its current expectations and projections about future events and financial trends that it believes may affect its financial condition, results of operations, business strategy and financial needs. The forward-looking statements can be affected by inaccurate assumptions or by known or unknown risks, uncertainties and assumptions due to a number of factors.

These forward-looking statements speak only as of the date on which they are made, and except to the extent required by federal securities laws, we undertake no obligation to update any forward-looking statements to reflect events or circumstances after the date on which the statement is made or to reflect the occurrence of unanticipated events. In addition, we cannot assess the impact of each factor on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. All subsequent written and oral forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by the cautionary statements contained in this annual report.

PART I

Item 1. Business

We were incorporated in the State of Nevada on September 24, 2008 as JB Clothing Corporation. Until July 10, 2009, our principal business objective was the offering of active/leisure fashion design clothing.

On July 10, 2009 we abandoned our efforts in the field of active/leisure fashion design clothing when we acquired 100% of the share capital of Entest BioMedical, Inc., a California corporation, (“Entest CA”) from Bio-Matrix Scientific Group, Inc. (“BMSN”) for consideration consisting of 10,000,000 shares of the common stock of the Company and the cancellation of 10,000,000 shares of the Company owned and held by Mr. Rick Plote.

As a result of this transaction, the former stockholder of Entest CA held approximately 70% of the voting capital stock of the Company immediately after the transaction. For financial accounting purposes, this acquisition was a reverse acquisition of the Company by Entest CA under the purchase method of accounting, and was treated as a recapitalization with Entest CA as the acquirer..

Upon acquisition of Entest CA, we abandoned our efforts in the field of active/leisure fashion design clothing. On July 12, 2009 we adopted the name of Entest CA when we changed our name to Entest BioMedical, Inc. On June 18, 2015 Entest established Zander Therapeutics, Inc., a then wholly owned subsidiary. Zander was established to engage primarily in the development and commercialization of veterinary medical therapies which we intend to license from other entities as well as develop internally

~~The Company~~FORWARD-LOOKING ~~changed its name to Entest Group, Inc. on February 12, 2018.~~STATEMENTS

~~On May~~This 5,annual ~~2018,~~report ~~The~~contains ~~Company~~forward-looking ~~declared~~statements. ~~the~~These ~~distribution~~statements onrelate ato ~~pro~~future ~~rata~~events ~~basis~~or our future financial performance. In some cases, you can identify forward-looking statements by terminology such as a“may”, ~~dividend~~“should”, in“expects”, ~~kind~~“plans”, of“anticipates”, 3“believes”,~~000~~ “estimates”,~~000~~ of“predicts”, “potential” or “continue” or the ~~common~~negative ~~shares~~ of ~~Zander~~these ~~Therapeutics,~~terms ~~Inc~~or other comparable terminology. These statements are only predictions and involve known and unknown risks, ~~par~~uncertainties ~~value~~and ~~$0.0001~~other factors, ~~currently~~including ~~owned~~the byrisks ~~Entest~~in ~~Group~~the section entitled “Risk Factors” that may cause our or our industry’s actual results, ~~Inc.~~levels of activity, performance or achievements to: be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements.

~~(a) Holders~~Although ofwe ~~record~~believe ofthat the ~~outstanding~~expectations ~~common~~reflected ~~shares~~in the forward-looking statements are reasonable, we cannot guarantee future results, levels of ~~the~~activity, ~~Company~~performance or achievements. Except as required by applicable law, including the securities laws of the ~~record~~United ~~date~~States, ~~which~~we isdo ~~May~~not ~~30,~~intend ~~2018~~to update any of the forward-looking statements to conform these statements to actual results.

~~(b) Holders~~Our offinancial ~~record~~statements ofare ~~the~~stated ~~shares~~in ofUnited ~~any~~States ~~outstanding~~Dollars ~~series~~(US$) ofand ~~the~~are ~~preferred~~prepared ~~shares~~in ofaccordance ~~the~~with ~~Company~~United asStates ofGenerally ~~the~~Accepted ~~record~~Accounting ~~date, which is May 30, 2018~~Principles.

~~Shareholders of~~In ~~the~~this ~~Company~~annual ~~shall~~report, ~~receive~~unless ~~one~~otherwise ~~(1)~~specified, ~~common~~all ~~share~~dollar ofamounts ~~Zander~~are ~~Therapeutics,~~expressed ~~Inc.~~in ~~for~~United ~~each~~States 17dollars ~~common~~ and~~/or~~ ~~preferred~~all ~~shares~~references ofto ~~the Company held as of the record date. The distribution of the 3,000,000~~ “common shares” ofrefer ~~Zander Therapeutics, Inc.~~ to the common ~~and~~ ~~preferred~~shares ~~shareholders~~in ofour ~~the~~capital ~~Company occurred on June 11, 2018 ("Distribution Date")~~stock.

As a ~~result~~used ofin ~~the~~this ~~payment~~current ofreport ~~the~~and ~~abovementioned~~unless ~~property~~otherwise ~~dividend~~indicated, the ~~Company’s~~terms ~~percentage of ownership of Zander fell below 50% resulting in~~ “the ~~deconsolidation of Zander as of the Distribution Date. As of the Distribution Date all assets and liabilities attributable to Zander were derecognized by the~~ Company~~. The Company recognized a $10~~”,~~034~~ ~~gain as a result of the deconsolidation. The Property dividend may be deemed to have occurred with a related party as the recipients were shareholders of Entest~~“we”, ~~including the~~“us” ~~Chairman~~ and ~~Chief~~“our” ~~Executive~~mean ~~Officer of~~ Entest ~~and Regen Biopharma~~Group, Inc., ~~which~~unless isotherwise ~~a company under common control with Entest~~indicated.

~~The Company’s~~PART remaining share of Zander , which consists of 5,000,000 shares of Zander’s Series M Preferred Stock (“Zander M Stock”) is accounted for under the Equity Method as of the Distribution Date. The Zander M Stock is carried a Fair Value and the carrying value is increased by the Company’s proportionate share of earnings of Zander and decreased by cash dividends paid by Zander as well as the Company’s proportionate share of losses of Zander up to the carrying value . As of August 31, 2018 the carrying value of the Zander M Stock has been decreased by the Company’s proportionate share of the losses of Zander and is 0. As of August 31, 2018 Entest beneficially owns 34.82% of the share equity of Zander.I

~~As of~~ITEM ~~November~~1. ~~16, 2018 the Company is a “shell company” as that term is defined in Rule 12b-2 of the Securities and Exchange Act which is a registrant that has:~~BUSINESS

~~(1) No~~General ~~or nominal operations; and~~Overview

~~(2) Either:~~We were incorporated in the State of Nevada on September 24, 2008 as JB Clothing Corporation. Until July 10, 2009, our principal business objective was the offering of active/leisure fashion design clothing.

On July 10, 2009 we abandoned our efforts in the field of active/leisure fashion design clothing when we acquired 100% of the share capital of Entest BioMedical, Inc., a California corporation, (i“Entest CA”) No orfrom ~~nominal~~Bio-Matrix ~~assets;~~Scientific Group, Inc. (“BMSN”) for consideration consisting of 10,000,000 shares of the common stock of the Company and the cancellation of 10,000,000 shares of the Company owned and held by Mr. Rick Plote. On July 12, 2009, the Company changed its name to Entest BioMedical, Inc.

~~(ii) Assets~~On ~~consisting~~June ~~solely~~18, of2015 ~~cash~~Entest established Zander Therapeutics, Inc., a then wholly owned subsidiary. Zander was established to engage primarily in the development and ~~cash~~commercialization ~~equivalents;~~of orveterinary medical therapies which we intend to license from other entities as well as develop internally

~~(iii) Assets~~The ~~consisting~~Company ofchanged ~~any~~its ~~amount~~name ofto ~~cash~~Entest ~~and~~Group, ~~cash~~Inc. ~~equivalents~~on ~~and~~February ~~nominal~~12, ~~other assets~~2018.

~~The Company's~~On ~~current~~May ~~business~~5, ~~strategy~~2018, isthe toCompany ~~acquire~~declared ~~an operating company seeking~~ the ~~perceived~~distribution ~~advantages~~on ~~of being~~ a ~~publicly~~pro ~~held corporation.~~rata Nobasis ~~assurance~~as ~~can~~a bedividend ~~given~~in ~~that~~kind ~~such~~of ~~an acquisition shall occur or~~3,000,000 ifof ~~such~~the ancommon ~~acquisition~~shares ~~were~~of toZander ~~occur~~Therapeutics, itInc., ~~would occur~~par onvalue ~~terms~~$0.0001, ~~and~~currently ~~conditions~~owned ~~beneficial~~by toEntest ~~the~~Group, ~~Company or its shareholders.~~Inc

~~Distribution methods~~Shareholders of the ~~products~~Company received one (1) common share of Zander Therapeutics, Inc. for each 17 common and/or ~~services:~~preferred shares of the Company held as of the record date. The distribution of the 3,000,000 common shares of Zander Therapeutics, Inc. to the common and preferred shareholders of the Company occurred on June 11, 2018.

~~Entest currently~~As ~~provides~~a noresult ~~product~~of orthe ~~service~~payment of the abovementioned property dividend, the Company’s percentage of ownership of Zander fell below 50% resulting in the deconsolidation of Zander and during the quarter ended November 30, 2018, the Company divested itself of its Zander stock.

3 Table of Contents

~~Competitive business~~On ~~conditions~~November 15, 2018, David Koos, Regen BioPharma Inc., Bostonia Partners Inc., Sherman Family Trust, Dunhill Ross Partners Inc., Bio-Technology Partners Business Trust (collectively, the “Sellers”) and ~~Entest's~~Peiwen ~~competitive~~Yu ~~position~~(the in“Buyer”) entered into a stock purchase agreement (the ~~industry~~“SPA”), pursuant to which the Sellers agreed to sell and ~~methods~~the Buyer agreed to purchase an aggregate of ~~competition~~23,733,334 shares of common stock, 667 shares of Series AA preferred stock, 534 shares of Series AAA preferred stock and 1,001,533 shares of Non-Voting Preferred Stock of Entest from the Seller for an aggregate purchase price of $325,000. The closing of the transactions contemplated by the SPA occurred on November 27, 2018.

~~The Company~~As ~~will~~contemplated ~~face~~by ~~vast competition from other shell companies that desire to seek a potential business combination with a private company seeking~~ the ~~perceived~~SPA, ~~advantages of being a publicly held corporation. The Company will be~~ in aNovember ~~highly~~2018, ~~competitive~~David ~~market for~~Koos aresigned ~~small~~as ~~number~~Chairman, ofChief ~~business~~Executive ~~opportunities~~Officer, ~~which could reduce the likelihood of consummating a successful business combination. A large number of established and well-financed entities~~President, ~~including~~Acting ~~small~~Chief ~~public~~Financial ~~companies~~Officer and ~~venture~~Secretary ~~capital firms, are active in mergers and acquisitions~~ of ~~companies~~Entest ~~that may be desirable target candidates for us. Nearly all these entities have significantly greater financial resources, technical expertise~~ and ~~managerial~~Peiwen ~~capabilities~~Yu ~~than~~became weas ~~do;~~a ~~consequently~~director, weChief ~~will~~Executive beOfficer ~~at a competitive disadvantage in identifying possible business opportunities~~ and ~~successfully~~President ~~completing~~of ~~a business combination~~Entest. ~~These competitive factors may reduce the likelihood of our identifying and consummating a successful business~~

~~combination~~Our principal executive offices are located at No. 911 Bao’an Book City, Xinqiao Street Central Road, Bao’an District, Shenzhen, China. Our telephone number is 86137 0963 1109. We do not have a corporate website.

~~Need for~~Our ~~any~~Current ~~government approval of principal products or services, effect of existing or probable governmental regulations on the business~~ Business

~~The Company~~Our iscompany ~~unaware~~currently ofdoes not have any ~~government~~operations ~~approval~~and ~~currently~~has ~~required~~not inactively ~~order~~conducted any operations for the ~~Company~~year ended August 31, 2019. Our company’s business plan for the next 12 months and beyond such time is to ~~complete~~seek annew ~~acquisition~~business ofopportunities or to engage in a business combination with an ~~operating~~ unidentified company. The ~~Company~~analysis isof ~~subject~~new business opportunities will be undertaken by or under the supervision of our company’s management. As of the date of this filing, our company has not entered into any definitive agreement with any party, nor have there been any specific discussions with any potential business combination candidate regarding business opportunities for our company. There can be no assurance that our company will be able to ~~federal~~identify and ~~state~~acquire ~~securities~~any ~~laws~~business entity. Even if we successfully acquire a business entity, there is no assurance that we can generate revenue and become profitable.

~~Amount spent during the last fiscal year on research and development activities~~Employees

~~During~~ As of August 31, 2019, we have no employees. Other than our sole officer and director who is donating their time to the ~~fiscal~~development ~~year~~of ~~ended~~our ~~August~~company 31and are able to fulfil part-time requirements. We have no employees, ~~2018~~and do not foresee hiring employees in the ~~consolidated~~near ~~Company~~future. ~~expended~~We ~~$949~~will be engaging independent contractors as needed who,~~584~~ onunder ~~research~~our ~~and~~direction, ~~development~~will ~~activities~~fulfill the requirements of engagements that exceed our officers' time constraints.

~~Costs and~~ITEM ~~effects~~1A. ofRISK ~~compliance with environmental laws (federal, state and local);~~FACTORS

~~Entest has not~~As ~~incurred~~a ~~any~~“smaller ~~unusual~~reporting orcompany”, ~~significant~~we ~~costs~~are ~~to remain in compliance with any environmental laws and does~~ not ~~expect to~~required ~~incur any unusual or significant costs~~ to ~~remain~~provide inthe ~~compliance~~information ~~with~~required ~~any~~by ~~environmental~~this ~~laws in the foreseeable future~~Item.

~~Number of~~ITEM ~~total~~1B. ~~employees~~UNRESOLVED ~~and~~STAFF ~~number of full-time employees~~COMMENTS

As of ~~November~~a ~~16,~~“smaller ~~2018~~reporting company”, ~~the~~we ~~Company~~are ~~has~~not 1required ~~employee~~to ofprovide ~~which~~the 1information isrequired ~~partl~~by ~~time~~this Item.

~~Sources and~~ITEM ~~availability~~2. ~~of raw materials and the names of principal suppliers~~PROPERTIES

~~Entest currently~~Our ~~has~~principal noexecutive ~~need~~office ~~for~~location ~~raw~~and ~~materials~~mailing oraddress ~~supplies~~is No. 911 Bao’an Book City, Xinqiao Street Central Road, Bao’an District, Shenzhen, China. The office is provided by our sole officer and director, Mr. Peiwen Yu, free of charge.

~~Patents, trademarks,~~ITEM ~~licenses,~~3. ~~franchises,~~LEGAL ~~concessions, royalty agreements or labor contracts, including duration.~~PROCEEDINGS

~~Entest possesses~~From notime ~~patents~~to ortime, ~~trademarks~~we may become involved in litigation relating to claims arising out of our operations in the normal course of business. ~~Entest~~We ~~has~~are not ~~been~~involved ~~granted~~in any ~~license,~~pending ~~franchise~~legal proceeding or ~~concession.~~litigation ~~Entest~~and, to the best of our knowledge, no governmental authority is ~~not~~contemplating any proceeding to which we are a party and which would reasonably be likely to ~~any royalty~~have ~~agreement~~a material adverse effect on our company. To date, our company has never been involved in litigation, as either a party or ~~labor~~a ~~contract~~witness, nor has our company been involved in any legal proceedings commenced by any regulatory agency against our company.

~~Item 2~~ITEM 4. ~~Properties~~MINE SAFETY DISCLOSURES

~~On November~~Not ~~1, 2011, the Company entered into an agreement to lease approximately 2,320 square feet of office space beginning December 1, 2011 for a period of five years~~Applicable.

~~Rent to~~4 beTable ~~charged~~of ~~to the Company pursuant to the lease is as follows:~~Contents

~~$2,996 per~~PART ~~month for the period beginning December 1, 2011 and ending November 30, 2012~~II

~~$3,241 per~~Our ~~month~~common shares were listed for quotation on the ~~period~~Pink ~~beginning~~Sheets ~~December~~of 1,the ~~2013~~OTC ~~and~~Markets ~~ending~~under ~~November~~the 30symbol “ETNI”. Our shares were originally listed for quotation on August 11, ~~2014~~2009.

~~$3,371 per~~There ~~month~~is no established current public market for the ~~period~~shares ~~beginning~~of ~~December~~our 1,common ~~2014~~stock. There can be no assurance that a liquid market for our securities will ever develop. Transfer of our common stock may also be restricted under the securities or blue sky laws of various states and ~~ending~~foreign ~~November~~jurisdictions. 30Consequently, ~~2015~~investors may not be able to liquidate their investments and should be prepared to hold the common stock for an indefinite period of time.

~~$3,506 per~~Our ~~month~~shares ~~for~~are ~~the~~issued ~~period~~in ~~beginning~~registered ~~December~~form. 1Securities Transfer Corporation at 2901 Dallas Pkwy, ~~2015~~Plano, TX 75093 (Telephone: (469) 633-0101) is the registrar and ~~ending~~transfer ~~November~~agent ~~30,~~for ~~2016~~our common shares.

4On December 16, 2019, the shareholders’ list showed 186 registered shareholders with 49,171,083 shares of common stock outstanding.

~~On November~~Dividend ~~27, 2016 the lease was extended until November 30, 2021~~Policy

~~Rent to~~We behave ~~charged~~not topaid any cash dividends on our common stock and have no present intention of paying any dividends on the ~~Company~~shares ~~pursuant~~of our common stock. Our current policy is to retain earnings, if any, for use in our operations and in the ~~extension~~development isof asour ~~follows:~~business. Our future dividend policy will be determined from time to time by our board of directors.

~~$2,996 per~~Equity ~~month~~Compensation ~~for~~Plan ~~the period beginning December 1, 2016 and ending November 30, 2017~~Information

~~$3,116 per~~We ~~month~~do ~~for~~not ~~the~~have ~~period~~any ~~beginning~~equity ~~December~~compensation ~~1, 2017 and ending November 30, 2018~~plans.

~~$3,241 per~~Recent ~~month~~Sales ~~for~~of ~~the~~unregistered ~~period beginning December 1, 2018 and ending November 30, 2019~~securities

~~$3,371 per~~We ~~month~~did ~~for~~not sell any equity securities which were not registered under the ~~period~~Securities ~~beginning~~Act ~~December~~during 1the year ended August 31, 2019 ~~and~~that ~~ending~~were ~~November~~not 30otherwise disclosed on our quarterly reports on Form 10-Q or our current reports on Form 8-K filed during the year ended August 31, ~~2020~~2019

~~$3,506 per~~Issuer ~~month~~Purchases ~~for~~of ~~the~~Equity ~~period beginning December 1, 2020 and ending November 30, 2021~~Securities

~~This property~~We isdid ~~utilized~~not aspurchase ~~office~~any ~~space.~~of ~~The~~our ~~Company~~shares ~~believes~~of ~~that~~common ~~the~~stock ~~foregoing~~or ~~property~~other issecurities ~~adequate~~during toour ~~meet~~fourth ~~its~~quarter ~~current~~of ~~needs~~our fiscal year ended August 31, 2019.

~~Item 3~~ITEM 6. ~~Legal~~SELECTED ~~Proceedings~~FINANCIAL DATA

~~None~~As a “smaller reporting company”, we are not required to provide the information required by this Item.

~~Item 4.~~5 ~~Submission~~Table of ~~Matters to a Vote of Security Holders~~Contents

~~No matter~~ITEM ~~was~~7. ~~submitted~~MANAGEMENT’S ~~during~~DISCUSSION ~~the~~AND ~~fourth~~ANALYSIS ~~quarter~~OF ofFINANCIAL ~~the~~CONDITION ~~fiscal~~AND ~~year~~RESULTS ~~covered~~OF ~~by this report to a vote of security holders, through the solicitation of proxies or otherwise.~~OPERATIONS

~~PART II~~The following discussion should be read in conjunction with our financial statements, including the notes thereto, appearing elsewhere in this annual report. The following discussion contains forward-looking statements that reflect our plans, estimates and beliefs. Our actual results could differ materially from those discussed in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to those discussed below and elsewhere in this Annual Report. Our audited financial statements are stated in United States Dollars and are prepared in accordance with United States Generally Accepted Accounting Principles.

~~Item 5.~~Results ~~Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases~~ of ~~Equity Securities~~Operations

The Company~~’s common~~ ~~stock~~has isnot aconducted ~~"penny~~any ~~stock,"~~active asoperations ~~defined~~during ~~in Rule 3a51-1 under~~ the ~~Exchange~~year ~~Act.~~ended ~~The~~August ~~penny stock rules require a broker-dealer~~31, ~~prior~~2019. toNo arevenue ~~transaction~~has inbeen agenerated ~~penny~~by ~~stock not otherwise exempt from~~ the ~~rules,~~Company towithin ~~deliver~~such aperiod. ~~standardized risk~~It ~~disclosure~~is ~~document~~unlikely ~~that provides information about penny stocks and~~ the ~~nature~~Company ~~and~~will ~~level~~have ofany ~~risks~~revenues inunless ~~the~~it ~~penny~~is ~~stock~~able ~~market. The~~to ~~broker-dealer~~effect ~~also~~an ~~must~~acquisition ~~provide~~or ~~the~~merger ~~customer~~ with ~~current~~an ~~bid~~operating ~~and offer quotations for the penny stock~~company, ~~the compensation~~ of ~~the~~ ~~broker-dealer~~which ~~and~~there ~~its~~can ~~sales~~be ~~person~~no inassurance. ~~the~~It ~~transaction,~~is ~~and monthly account statements showing the market value of each penny stock held in the customer'~~management’s ~~account.~~assertion ~~In addition, the penny stock rules require~~ that ~~the~~these ~~broker-dealer,~~circumstances ~~not~~raises ~~otherwise~~substantial ~~exempt from~~doubt ~~such~~about ~~rules, must make a special written determination that~~ the ~~penny stock is suitable for the purchaser and receive the purchaser'~~Company’s ~~written~~ability ~~agreement~~ to ~~the~~continue ~~transaction.~~as ~~These disclosure rules have the effect of reducing the level of trading activity in the secondary market for~~ a ~~stock~~going ~~that becomes subject to the penny stock rules~~concern. SoThe ~~long~~Company’s asplan ~~the common stock~~ of ~~the~~operation ~~Company is~~for ~~subject to~~ the ~~penny~~next ~~stock~~twelve ~~rules,~~months itshall ~~may~~ be ~~more difficult~~ to ~~sell~~locate ~~common~~suitable ~~stock~~acquisition ~~of the Company~~candidates.

~~The Company’s authorized~~For ~~capital~~the ~~stock~~year ~~consists~~ended ofAugust ~~500~~31,~~000,000~~ ~~shares~~2019 ofcompared ~~common stock~~ with athe ~~par~~year ~~value~~ended ~~$0.0001,~~August ~~and 5~~31,~~000,000 shares~~ of preferred stock with a par value $0.0001 per share (of which 100,000 are designated as Series AA Preferred Stock, 4,400,000 are designated as Series B Preferred Stock and 300,000 are designated as Series AAA Preferred Stock) and 3,000,000 shares authorized of Non Voting Convertible Preferred Stock, par value $1.00 . As of November 16,2018 Entest BioMedical, Inc. had 49,170,472 common shares outstanding, 728, 009 Series B Preferred shares outstanding , 667 Series AA preferred shares outstanding, 534 Series AAA preferred shares outstanding, and 1001533 shares of the Company’s Non Voting Convertible Preferred Stock outstanding.

~~(a)~~The ~~Our~~following ~~common~~summary ~~stock is traded on the OTC Pink Tier~~ of ~~OTC~~our ~~Markets~~results ~~under the symbol "ETNI”. Below is the range~~ of ~~high~~operations ~~and~~should ~~low~~be ~~price~~read ~~information~~in ~~for~~conjunction with our ~~common~~financial ~~equity~~statements for ~~each quarter within~~ the ~~last~~year ~~two~~ended ~~fiscal~~August ~~years~~31, as2019, ~~reported~~which byare ~~OTC~~included ~~Markets~~herein.

5Our operating results for the year ended August 31, 2019 and the year ended August 31, 2018 and the changes between those periods for the respective items are summarized as follows:

September 1, 2017 to August 31, 2018	High		Low
	Year Ended
First Quarter	$	0.0182	$	0.0068
	August 31,
Second Quarter		0.0205		0.0068
	2019		2018			Changes ($)
Third Quarter		0.0405		0.0092
Operating expenses	$	40,118	$	1,520,899		$	(1,480,781	)
Fourth Quarter	$	0.054	$	0.011
Other Income	$	231,736	$	43,415		$	188,321
September 1, 2016 to August 31, 2017		High		Low
Net Income (loss)	$	191,618	$	(1,477,484	)	$	1,669,102
First Quarter	$	0.0919	$	0.0038
Second Quarter		0.0559		0.02
Third Quarter		0.055		0.015
Fourth Quarter	$	0.0201	$	0.045

~~Holders~~The Company has not conducted any operations during the year ended August 31, 2019. Revenues from operations were $0 for the years ended August 31, 2019 and 2018

~~As of~~For the year ended August 31, ~~2018~~2019, ~~there~~operating ~~were~~expenses ~~approximately~~of $40,118, ~~holders~~consisted of ~~our~~professional ~~Common~~fees ~~Stock~~of $22,689 and general and administrative expenses of $17,429.

~~Dividends~~For the year ended August 31, 2019, other income of $231,736, consisted of a gain on write off of accounts payable of $23,629, gain on disposition of Zander Therapeutics, Inc. of $188,589, rental income of $22,000, loss on disposition of Entest Biomedical Inc. of $947, write off accrued interest receivable of $1,040 and interest expense of $495.

~~No cash~~The ~~dividends~~net ~~were~~income ~~paid~~for ~~during~~ the ~~fiscal~~ year ~~ending~~ended August 31, ~~2018.~~2019 Wewas ~~do not expect to declare cash dividends in the immediate future~~$191,618.

~~Recent Sales~~For the year ended August 31, 2018, operating expenses of ~~Unregistered~~$1,520,899, ~~Securities~~consisted of professional fees of $310,020, general and administrative expenses of $261,295 and research and development expenses of $949,584.

~~On September~~For 8the year ended August 31, ~~2017~~2018, ~~the~~other ~~Company~~income ~~issued~~of 2$43,~~500~~415 consisted of rental income of $66,000, ~~Common~~gain ~~Shares~~on ~~(“Shares”)in~~deconsolidation ~~connection~~of ~~with~~Zander aTherapeutics, ~~conversion~~Inc. of 25$10,034, gain on sale of securities of $30,000, ~~Non Voting~~interest ~~Convertible~~income ~~Preferred~~of ~~Shares~~$132, equity losses of Zander Therapeutics, Inc. of $61,428, and interest expenses of $1,323.

The ~~Shares~~ ~~were~~net ~~issued~~loss ~~pursuant~~for ~~to Section 4(a) (2) of~~ the ~~Securities~~year ~~Act~~ended ofAugust ~~1933~~31, as2018, ~~amended (the “Act”). No underwriters were retained to serve as placement agents for the sale. The shares were sold directly through our management. No commission or other consideration~~ was ~~paid in connection with the sale of the shares~~$1,477,848. There was no advertisement or general solicitation made in connection with this Offer and Sale of Shares. A legend was placed on the certificate that evidences the Shares stating that the Shares have not been registered under the Act and setting forth or referring to the restrictions on transferability and sale of the Shares.

~~Item~~ 6. ~~Selected~~Table ~~Financial~~of ~~Data~~Contents

~~As we~~The ~~are~~increase ain ~~“smaller~~net ~~reporting~~income ~~company”~~for the year ended August 31, 2019, as ~~defined~~compared byto ~~Rule~~the ~~229.10(f)(1)~~same period ended August 31, we2018, ~~are not~~was ~~required~~primarily due to ~~provide~~other income realized, from the ~~information required~~ceasing byof ~~this~~prior ~~Item~~operations, disposition of subsidiaries and change of control during the first quarter ended November 30, 2018.

~~Item 7.~~Liquidity ~~Management’s Discussion~~ and ~~Analysis~~Capital ~~of Financial Condition and Results of Operations~~ Resources

~~As of~~Working ~~August 31, 2017, we had Cash in the amount of $86,559 and as of August 31, 2018 we had Cash in the amount of $267.~~Capital

The decrease in Cash of approximately 99.7% is primarily attributable to the derecognition of the assets of Zander Therapeutics, Inc. which was deconsolidated from the Company on June 11, 2018.

	August 31, 2019			August 31, 2018			Changes ($)
Cash	$	-		$	267		$	(267	)
Working capital (deficiency)	$	(32,671	)	$	(245,711	)	$	213,040
Total assets	$	-		$	9,307		$	(9,307	)
Total liabilities	$	32,671		$	255,018		$	(222,347	)
Total stockholders' equity (deficit)	$	(32,671	)	$	(245,711	)	$	213,040

The decrease in working capital deficit was primarily attributed to decreased liabilities from the disposition of prior operations and the change of control occurred in November 2018. As of August 31, ~~2017~~2019, weour ~~had~~liabilities ~~Accrued~~decreased ~~Interest~~$222,347, ~~Receivable~~from $255,018, as of August 31, 2018, to $~~908~~32,671. The decrease in liabilities is attributable to a decrease in notes payable of $19,601, a decrease of accounts payable and accrued liabilities of $206,943, a decrease of unearned rental income of $17,000 and an increase in due to related party of $21,197. As of August 31, 2019, our current assets decreased $9,307, from $9,307, as of August 31, 2018, weto ~~had~~$0. ~~Accrued~~The ~~Interest~~decrease ~~Receivable~~is ofprimarily attributed to the $8,000 in prepaid expenses and $1,040 accrued interest receivable at August 31, 2018.

~~The increase~~Cash in Accrued Interest Receivable of approximately 14.2% is attributable to $132 of interest earned by the Company during the quarter ended February 28, 2018 resulting from a short term loan made by the Company, the principal on such loan paid during the quarter ended February 28, 2018.Flows

As of August 31, 2017 we had Prepaid Expenses of $58,652 and as of the end of the same period ended 2018 we had Prepaid Expenses of $8,000.

	Year Ended
	August 31,
	2019			2018			Changes ($)
Cash Flows used in Operating Activities	$	(3,959	)	$	(1,490,101	)	$	(1,486,142	)
Cash Flows Provided (Used) by Investing Activities	$	1,937		$	(2,357	)	$	4,294
Cash Flows provided by Financing Activities	$	1,755		$	1,406,166		$	(1,404,411	)
Net Change in Cash During Period	$	(267	)	$	(86,292	)	$	(86,025	)

~~The decrease~~Cash inFlow ~~Prepaid~~from ~~Expenses~~Operating ~~of approximately 86.3% is primarily attributable to $50,652 of fees prepaid to consultants during the fiscal year ended 2017.~~Activities

6The net cash used in operating activities for the year ended August 31, 2019 was attributed to a net income of $191,618, increased due to an increase in expenses paid by a related party of $21,197, loss on disposition of Entest Biomedical Inc. of $947 and decreased by gain on write off of accounts payable of $23,629, gain on disposition of Zander Therapeutics, Inc. of $188,589 and a net change in operating assets and liabilities of $11,503.

~~As of~~The net cash used in operating activities for the year ended August 31, ~~2017~~2018 wewas ~~had~~attributed ~~Securities~~to ~~Available~~a ~~for~~net ~~Sale~~loss of $1,477,484, increased due to an increase in ~~the~~gain ~~amount~~attributable to deconsolidation of $~~190~~10,~~050~~034, gain lost in deconsolidation of $332,638 and asdecreased by equity in losses of ~~August~~Zander 31Therapeutics, ~~2018~~Inc. weof ~~had~~$61,428 ~~Securities Available~~and ~~for~~a ~~Sale~~net change in ~~the~~operating ~~amount~~assets and liabilities of $0268,627.

~~The decrease~~Cash inFlow ~~Securities~~from ~~Available~~Investing ~~for Sale is attributable to the sale by the Company of 3,500,000 of the Series A Preferred shares of Regen Biopharma, Inc.to Zander Therapeutics, Inc.~~Activities

~~David R.~~Net ~~Koos,~~cash ~~the~~from ~~Chairman~~investing ~~and~~activities ~~Chief~~was ~~Executive~~$1,937, ~~Officer~~for of the ~~Company~~year ended August 31, ~~serves~~2019, inderived ~~the~~from ~~same~~proceeds ~~capacity~~from ata ~~Regen~~net ~~Biopharma,~~cash ~~Inc.~~received ~~and~~for ~~Zander Therapeutics,~~divestiture of Entest Biomedical Inc.

~~As of~~Net ~~August~~cash ~~31,~~used ~~2017~~by weinvesting ~~had~~activities ~~Notes~~was ~~Payable of~~ $132,~~501~~357, ~~and~~for asthe ofyear ended August 31, 2018, wederived ~~had~~from ~~Notes~~proceeds ~~Payable~~from a net gain on sale of ~~$19,601~~securities received prior to deconsolidation.

~~The increase~~7 inTable ~~Notes Payable~~ of approximately 45.1% is attributable to the incurrence of an additional $2,500 of principal indebtedness from the Company’s Chairman and incurrence of an additional $3,600 of principal indebtedness from an entity controlled by the Company’s Chairman.Contents

~~As of~~Cash ~~August~~Flow ~~31,~~from ~~2017~~Financing ~~we had Accrued Expenses of $269,398 and as of August 31, 2018 we had Accrued Expenses of $181,904.~~Activities

~~The reduction~~Net incash ~~accrued~~from ~~expenses~~financing ofactivities ~~approximately~~was ~~32.4%~~$1,755, isfor ~~primarily attributable to payment during~~ the year ended August 31, ~~2018~~ 2019, derived from proceeds from contributed capital of $881,~~000~~821 ofoffset ~~salary~~by ~~accrued~~repayment ~~but~~of ~~unpaid~~bank tooverdraft ~~David~~of ~~R. Koos~~$66, ~~the~~compared ~~Company’s~~to ~~sole~~net ~~officer~~cash asfrom ~~well~~financing asactivities ~~derecognition~~ of $~~818~~1,406,166, ~~of accrued~~for ~~interest during~~ the year ended August 31, 2018, ~~attributable~~derived tofrom ~~the~~proceeds ~~deconsolidation~~from ofcommon ~~Zander~~stock ~~Therapeutics~~issued from subsidiary of $1,400,000, ~~Inc.~~proceeds ~~offset by~~from ~~interest~~note ~~accrued~~payable ~~but~~of ~~unpaid~~$6,100 ~~due~~and onproceed ~~Notes~~from ~~payable~~bank overdraft of$66.

As of August 31, 2019 and 2018, we had ~~Unearned~~cash ~~Rental Income~~ of $~~17,000~~0 and ~~as of August 31~~$267, ~~2017 we had Unearned Rental Income of $0~~respectively.

~~The increase~~We inbelieve ~~Unearned~~that ~~Rental~~we ~~Income~~will isnot ~~attributable~~be able to ~~rental~~satisfy ~~income~~our ~~prepaid~~cash torequirements over the next twelve months. The Company byseeks ~~Regen~~to ~~Biopharma,~~acquire ~~Inc~~an operating company seeking the perceived advantages of being a publicly held corporation. ~~Regen~~No ~~Biopharma~~assurance can be given that such an acquisition shall occur or, ~~Inc~~ if such an acquisition were to occur, it would occur on terms and conditions beneficial to the Company or its shareholders. The Company is ~~under~~also ~~common~~dependent ~~control~~upon the receipt of capital investment or other financing to fund its ongoing operations and to execute its business plan of seeking a combination with a private operating company. In addition, the Company anticipates that it will be dependent upon certain related parties to provide continued funding and capital resources. If continued funding and capital resources are unavailable at reasonable terms, the Company may not be able to implement its plan of operations.

~~As of~~Critical ~~August~~Accounting ~~31,~~Policies ~~2018 we had a bank overdraft of $66~~ and ~~as of August 31, 2017 we had a bank overdraft of $0.~~Estimates

~~The increase~~Use ~~in bank overdraft is attributable to withdrawals~~ of ~~$66 in excess of the balance of a bank account maintained by the Company.~~Estimates

~~Revenues from~~The ~~continuing~~preparation ~~operations~~of ~~were~~financial $0statements ~~for~~in conformity with accounting principles generally accepted in the ~~year~~United ~~ended~~States ~~August~~of ~~31,~~America ~~2017~~requires management to make estimates and ~~-0-~~assumptions ~~for~~that affect the ~~year~~reported ~~ended~~amounts ~~August~~of ~~31,~~assets ~~2018~~and liabilities and disclosure of contingent liabilities at dates of the financial statements and the reported amounts of revenue and expenses during the periods. ~~Net~~Actual ~~Losses~~results could differ from ~~continuing~~ ~~operations~~these ~~were~~estimates. ~~$664,792~~Our ~~for~~significant ~~the~~estimates ~~year~~and ~~ended~~assumptions ~~August~~include 31depreciation, ~~2017~~stock-based compensation and ~~$1,477,484~~the ~~for~~valuation allowance relating to the ~~same~~Company’s ~~period~~deferred ~~ended~~tax ~~2018~~assets.

~~The increase~~Recently inIssued ~~Net~~Accounting Loss of approximately 122.2% is primarily attributable to Research and Development Fees incurred by Zander Therapeutics, Inc. during that period of the fiscal year during which Zander Therapeutics, Inc. was a consolidated subsidiary of the Company and recognition of the Company’s equity in the losses of Zander Therapeutics, Inc. during the period beginning June 11, 2018 and ending August 31, 2018. These losses were offset by gains on sale of investment securities and a one time gain of $10,034 recognized in connection with the deconsolidation of Zander Therapeutics, Inc.Pronouncements

7Reference is made to the “Recent Accounting Pronouncements” in Note 2 to the Financial Statements included in this report for information related to new accounting pronouncement, none of which had a material impact on our consolidated financial statements, and the future adoption of recently issued accounting pronouncements, which we do not expect will have a material impact on our consolidated financial statements.

~~As of~~Off-Balance ~~August~~Sheet ~~31, 2018 we had $267 cash on hand and current liabilities of $255,018 such liabilities consisting of Accounts Payable, Notes Payable, Amounts due to Others and Accrued Expenses.~~Arrangements

~~We feel~~As ~~we will not be able to satisfy our cash requirements over the next twelve months. The Company seeks to acquire an operating company seeking the perceived advantages~~ of ~~being~~August ~~a publicly held corporation. No assurance can be given that such an acquisition shall occur or~~31, ~~if such an acquisition were to occur~~2019, itwe ~~would~~do ~~occur~~not onhave ~~terms~~any ~~and~~off-balance ~~conditions~~sheet ~~beneficial to the Company or its shareholders~~arrangements.

~~As of~~ITEM ~~November~~7A. ~~16,~~QUANTITATIVE ~~2018~~AND weQUALITATIVE ~~are~~DISCLOSURES ~~not~~ABOUT ~~party~~MARKET ~~to any binding agreements which would commit Entest to any material capital expenditures.~~RISK

~~Item 7A.~~As ~~Quantitative~~a ~~and~~“smaller ~~Qualitative~~reporting ~~Disclosures~~company”, ~~About~~we ~~Market~~are ~~Risk~~not required to provide the information required by this Item.

~~As we~~8 ~~are~~Table aof ~~smaller reporting company, as defined by Rule 229.10(f)(1), we are not required to provide the information required by this Item.~~Contents

ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

~~Item 8.~~ENTEST ~~Financial~~GROUP, ~~Statements and Supplementary Data~~INC

~~REPORT OF~~Financial ~~INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM~~ Statements

To For the ~~Board~~year ofend ~~Directors~~August ~~and~~31, ~~Stockholders~~2019 ofand 2018

~~Entest Group,~~Index ~~Inc.~~to ~~(FKA~~the ~~Entest~~Audited ~~Biomedical,~~Financial ~~Inc.)~~Statements

Opinion on the Financial Statements

		Page

Reports of Independent Registered Public Accounting Firms		F-2-F-3

Balance Sheet as of August 31, 2019 and 2018		F-4

Statement of Operations for the years ended August 31,2019 and 2018		F-5

Statements of Stockholders' Deficit for the years ended August 31,2019 and 2018		F-6

Statements of Cash Flows for the years ended August 31,2019 and 2018		F-7

Notes to the Financial Statements		F-8

We have audited the accompanying balance sheets of Entest Group, Inc. (the “Company”) as of August 31, 2018 and August 31, 2017 and the related statements of operations, comprehensive income, stockholders’ equity, and cash flows for each of the years in the twoF-~~year~~1 ~~period~~Table ended August 31, 2018, and the related notes and schedules (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of August 31, 2018 and August 31, 2017, and the results of its operations and its cash flows for each of the years in the two-year period ended August 31, 2018 in conformity with accounting principles generally accepted in the United States of America.Contents

~~Basis for~~REPORT ~~Opinion~~OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

~~These financial~~To ~~statements are~~ the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board ~~(United States) (“PCAOB”) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations~~ of ~~the~~Directors ~~Securities~~ and ~~Exchange Commission and the PCAOB.~~

~~We conducted~~Stockholders ~~our audits in accordance with the standards~~ of ~~the~~Entest ~~PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement~~Group, ~~whether due to error or fraud~~Inc. The company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting, but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

~~Our audits~~Opinion included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on ~~a test basis, evidence regarding~~ the ~~amounts~~Financial and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.Statements

~~The accompanying~~We ~~financial statements~~ have ~~been~~audited ~~prepared~~the ~~assuming~~accompanying ~~that~~balance ~~the~~sheet ~~Company~~of ~~will~~Entest ~~continue~~Group, asInc. a(the ~~going~~“Company”) ~~concern.~~as Asof ~~discussed in~~August ~~Note~~31, 42019, toand the ~~financial~~related statements, ~~the~~of ~~Company~~operations, ~~has~~stockholders’ ~~no revenues~~deficit, ~~has~~and ~~negative~~cash ~~working~~flows ~~capital~~for atthe year ended August 31, ~~2018~~2019, ~~has~~and ~~incurred recurring~~the ~~losses~~related ~~and~~notes ~~recurring~~(collectively ~~negative~~referred ~~cash~~to ~~flow~~as ~~from~~the ~~operating~~financial ~~activities~~statements). In our opinion, ~~and~~the ~~has~~financial anstatements ~~accumulated~~present ~~deficit~~fairly, ~~which~~in ~~raises~~all ~~substantial doubt~~material ~~about~~respects, ~~its~~the ~~ability~~financial toposition ~~continue~~of the Company as aof ~~going~~August ~~concern.~~31, ~~Management’s~~2019, ~~plans~~and ~~concerning~~the ~~these~~results ~~matters~~of ~~are~~its ~~also~~operations ~~described~~and ~~in Note~~its 4.cash ~~The~~flows ~~financial~~for ~~statements~~the doyear ~~not~~ended ~~include~~August ~~any~~31, ~~adjustments~~2019, ~~that~~in ~~might~~conformity ~~result~~with ~~from~~accounting principles generally accepted in the ~~outcome~~United States of ~~this uncertainty~~America.

~~/s/ AMC~~Going ~~Auditing~~Concern

~~AMC Auditing We~~The accompanying financial statements have ~~served~~been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the financial statements, the Company has no revenues, has negative working capital at August 31, 2019, has incurred recurring negative cash flow from operating activities, and has an accumulated deficit which raises substantial doubt about its ability to continue as a going concern. Management’s ~~auditor~~plans ~~since~~concerning ~~2012~~these matters are also described in Note 1. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

~~Las Vegas,~~Basis ~~Nevada~~for Opinion

~~November 19,~~These ~~2018~~financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

9We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audit, we are required to obtain an understanding of internal control over financial reporting, but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

ENTEST GROUP,INC.
(Formerly called ENTEST BIOMEDICAL, INC.)
Consolidated Balance Sheet
	As of August 31, 2018		August 31, 2017
ASSETS
Current Assets
Cash	267		86,559
Accrued Interest Receivable	1,040		908
Current Portion of Prepaid Expenses	8,000		58,652
Accrued Rent Receivable	0		0
Total Current Assets	9,307		146,119
OTHER ASSETS
Available for Sale Securities	0		190,050
Long Term Portion Prepaid Expenses	0		0
TOTAL ASSETS	9,307		336,169
LIABILITIES AND STOCKHOLDERS' EQUITY
Current Liabilities
Accounts Payable	28,447		28,446
Notes Payable	19,601		13,501
Due to Other	8,000		8,000
Unearned Rental Income	17,000		0
Bank Overdraft	66		0
Accrued Expenses	181,904		269,398
Total Current Liabilities	255,018		319,345
TOTAL LIABILITIES	255,018		319,345
STOCKHOLDERS' EQUITY
Common Stock, authorized 500,000,000 shares as of August 31, 2017 and August 31, 2018; issued and outstanding 46,670,472(par value $0.0001) as of August 31, 2017 and 49,170,472 as of August 31, 2018	4,911		4,661
Preferred Stock ,par value $0.0001 5,000,000 shares authorized, Series AA Preferred Stock, 100,000 shares authorized, 667 shares, par value $0.0001, issued and outstanding at August 31, 2017 and as of August 31, 2018	0		0
Series B Preferred 4,400,000 shares authorized, 728,009 ( par value $0.0001) issued and outstanding as of August 31, 2018 and 728,009 issued and outstanding as of August 31, 2017	73		73
Series AAA Preferred, 300,000 shares authorized, $0.0001 par value 534 shares outstanding as of August 31, 2018 and as of August 31, 2017
NonVoting Convertible Preferred ($1 par value) 3,000,000 shares authorized as of August 31, 2018 and August 31, 2017 respectively, 1,001,533 and 1,026,533 issued and outstanding as of August 31, 2018 and August 31, 2017, respectively	1,001,533		1,026,533
Additional Paid in Capital	8,729,236		7,191,000
Contributed Capital	274,662		274,662
Accumulated Deficit	(10,256,126	)	(8,721,498	)
Accumulated Other Comprehensive Income	0		185,050
Total Stockholders' Equity Entest Biomedical, Inc.	(245,711	)	(39,519	)
Non Controlling Interest Zander Therapeutics Inc.	0		56,343
Stockholders Equity	(245,711	)	16,824
TOTAL LIABILITIES & STOCKHOLDERS' EQUITY	9,307		336,169
The accompanying Notes are an integral part of these Financial Statements

Our audit included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audit provides a reasonable basis for our opinion.

10/s/ Prager Metis CPAs, LLC

ENTEST GROUP,INC.
(Formerly called ENTEST BIOMEDICAL, INC.)
Consolidated Statement of Operations
	Year Ended		Year Ended
	August 31, 2018		August 31 2017
TOTAL REVENUE	0		0
COSTS AND EXPENSES
Research and Development	949,584		124,770
Rent Costs	37,032		37,482
General and Administrative	224,263		225,804
Consultant's Expenses	310,020		263,823
Total Costs and Expenses	1,520,899		651,879
OPERATING LOSS	(1,520,899	)	(651,879	)
OTHER INCOME AND EXPENSE
Rental income	66,000		60,000
Interest Income	132		1,056
Gain on Write Off of Accounts Payable			76,697
Loss on Issuance of Stock Below Fair Value			(107,700	)
Gain on Deconsolidation of Zander	10,034
Equity in Losses of Zander	(61,428	)
Gain on Sale of Securities	30,000
Interest Expense	(1,323	)	(42,966	)
TOTAL OTHER INCOME AND EXPENSE	43,415		(12,913	)
LOSS BEFORE INCOME TAXES	(1,477,484	)	(664,792	)
Income Taxes	0		0
NET LOSS
NET LOSS from continuing	(1,477,484	)	(664,792	)
Operations
Less: (Net Income) Loss attributable to non controlling interest in Zander Therapeutics, Inc.			105,374
NET LOSS available to common shareholders	(1,477,484	)	(559,418	)
BASIC AND DILUTED EARNINGS (LOSS) PER SHARE FROM CONTINUING OPERATIONS	(0.030	)	(0.013	)
WEIGHTED AVERAGE NUMBER COMMON SHARES OUTSTANDING	48987813		42551431
The accompanying Notes are an integral part of these Financial Statements

We have served as the Company’s auditor since 2019

11Las Vegas, Nevada

ENTEST GROUP, INC.
(Formerly called ENTEST BIOMEDICAL, INC.)
Consolidated Statement of Comprehensive Income
		Year Ended August 31,			Year Ended August 31,
		2018			2017
Net Income (Loss)	$	(1477484	)	$	(664,792	)
Add:
Unrealized Gains on Securities		0			277,100
Less:
Unrealized Losses on Securities		0			(92,050	)
Comprehensive Income attributable to Non Controlling Interest		0			0
Total Other Comprehensive Income (Loss)		0			185,050
Comprehensive Income	$	(1477484	)	$	(479,742	)
The accompanying Notes are an integral part of these Financial Statements

December 18, 2019

12F-2 Table of Contents

	Common				Series AA Preferred				Series AAA Preferred				Series B Preferred				Non Voting Convertible Preferred
	Shares		Amount		Shares		Amount		Shares		Amount		Shares		Amount		Shares			Amount			Additional Paid-in Capital			Contributed Capital		Accumulated Other Comprehensive Income (Loss)			Accumulated Deficit during the Development Stage			Non Controlling interest In Subsidiary			Total
Balance August 31, 2016		40,170,472		4,011		667		0		533		0		28,009		3		0			0			6,148,054			274,162		0			(7,405,099	)		0			(978,869	)
Common Shares issued to Consultant January 27, 2017		100000		10																				4490														4,500
Common Shares issued for debt February 7, 2017		1000000		100																				9900														10,000
Common Shares issued for debt February 10, 2017		2,000,000		200																				19,800														20,000
Common Shares issued to Consultant March 10, 2017		100000		10																				4810														4,820
Series B Preferred shares issued to consultant March 10, 2017														500000		50																						50
Series B Preferred shares issued to consultant March 10, 2017														100000		10																						10
Series B Preferred shares issued to consultant March 31, 2017														100000		10																						10
Common Stock Issued for Cash April 3, 2017		750000		75																				14,925														15,000
Common Stock of Subsidiary sold for Cash April 10, 2017																								20,000														20,000
Common Shares issued to Consultant May 30, 2017		100000		10																				3,390														3,400
Shares issued for Accrued Expenses May 30, 2017																		83000			83000																	83,000
Shares issued for Debt May 30, 2017																		840681			840681																	840,681
Beneficial Conversion Features recognized May 30, 2017																								576,804														576,804
Amortization of Beneficial Conversion Feature May 30, 2017																																(576,804	)					(576,804	)
Preferred Shares of Subsidiary issued to consultants June 20, 2017																								100														100
Preferred Shares of Subsidiary issued to employees June 15, 2017																								150														150
Common Shares of Subsidiary issued for Cash July 10, 2017																								100,000														100,000
Common Shares of Subsidiary issued to Consultant 7/10/2017																								50														50
Preferred Shares of Subsidiary Issued to Consultants July 10, 2017																								10														10
Common Shares issued to Consultants July 24, 2017		2450000		245																				97,510														97,755
Shares issued for Accrued Expenses July 24, 2017																		102852			102852																	102,852
Beneficial Conversion Features recognized July 24, 2017																								74,801														74,801
Amortization of Beneficial Conversion Feature July 24, 2017																																(74,801	)					(74,801	)
Preferred Shares of Subsidiary Issued to Consultants August 21, 2017																								140														140
Restricted Stock Expense Recognized During the Year Ended August 31, 2017																								64,709														64,709
Accumulated Other Comprehensive Income Recognized During the Year Ended
August 31, 2017																													185050									185,050
Loss on Issuance below Fair Value																								107,700														107,700
Net Loss for the Year Ended August 31, 2017																																(664,792	)					(664,792	)
Non Controlling Interest in Subsidiary																								(56,343	)										56343			0
Increase in Contributed Capital Year Ended 8/31/2017																											500											500
Balance August 31, 2017		46,670,472		4,661		667		0		533		0		728,009		73		1,026,533			1,026,533			7,191,000			274,662		185050			(8,721,498	)		56343			16,824
Common Shares issued for NonVoting Convertible Preferred Shares September 8, 2017		2,500,000		250														(25,000	)		(25,000	)		24,750														0
Common Shares of Subsidiary issued for Cash October 30, 2017																								900,000														900,000
Common Shares of Subsidiary issued for Cash February 5, 2018																								200,000														200,000
Common Shares of Subsidiary issued for Cash February 27, 2018																								300,000														300,000
Declaration of property Dividend May 5, 2018																																(57,143	)					(57,143	)
Payment of Property Dividend June 11, 2018																								57,143														57,143
Elimination of Noncontrolling Interest upon deconsolidation June 11, 2018																								56,343											(56,343	)		0
Sale of Securities of Securities Available for Sale																													(185,050	)								(185,050	)
Net Loss For Year Ended August 31, 2018																																(1,477,484	)					(1,477,484	)
Balalnce August 31, 2018		49,170,472		4,911		667		0		533		0		728,009		73		1,001,533			1,001,533			8,729,236			274,662		0			(10,256,126	)		0			(245,711	)
The accompanying Notes are an integral part of these Financial Statements

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

13To the Board of Directors and Stockholders of

ENTEST GROUP,INC.
(Formerly called ENTEST BIOMEDICAL, INC.)
Consolidated Statement of Cash Flow
(unaudited)
	Year Ended		Year Ended
	August 31, 2018		August 31, 2017
OPERATING ACTIVITIES
Net (loss)	(1,477,484	)	(664,792	)
Adjustments to reconcile net loss to net cash used by operating activities:
Increase(Decrease) in stock of subsidiary issued to employees			150
Increase(Decrease) in stock of subsidiary issued to consultants			300
Increase (Decrease) in Additional paid in Capital	0		64,709
Increase ( Decrease) in Issuance of Stock below Faie Value	0		107,700
increase (Decrease) in Preferred Stock issued for expenses	0		185,852
Increase (Decrease) in Preferred Stock issued to Consultants			70
(Increase) Decrease in Gain attributable to Deconsolidation	(10,034	)
(Increase) Decrease Cash Lost in Deconsolidation	(332,638	)
Equity in Losses of Zander	61,428
Increase (Decrease) Common Stock issued to Consultants			110,475
Changes in Operating Assets and Liabilities
(Increase) Decrease in Prepaid Expenses	(117,388	)	(50,652	)
Increase(Decrease) in Unearned Rent	17,000
Increase (Decrease) in Accounts Payable	454,494		(83,716	)
(Increase) Decrease in Accrued Rental Income Receivable	0		15,000
Increase (Decrease) in Accrued Expenses	(85,347	)	(157,566	)
(Increase )Decrease in Accrued Interest Receivable	(132	)	(909	)
(Increase) Decrease in Notes Receivable
Net Cash Provided (Used) in Operating Activities	(1,490,101	)	(473,380	)
Net Cash Provided ( Used) in Investing Activities:
Securities Purchased for Cash			(5,000	)
Gain on Sale of Securities received prior to deconsolidation	(2,357	)
Net Cash Provided ( Used) in Investing Activities:	(2,357	)	(5,000	)
FINANCING ACTIVITIES
Net Cash Provided (Used) in Financing Activities:
Common Stock issued for cash			15,000
Common Stock of Subsidiary issued for cash	1,400,000		120,000
Increase (Decrease) in Notes Payable	6,100		428,580
Increase(Decrease) Bank Overdraft	66
Increase (Decrease) in Contributed Capital			500
Net Cash Provided by Financing Activities	1,406,166		564,080
Net (Decrease) Increase in Cash	(86,292	)	85,700
Cash at Beginning of Period	86,559		859
Cash at End of Period	267		86,559
Supplemental Disclosure of Non CashInvesting and Financing Activities:
Common Stock Issued for Debt			30,000
Preferred Stock issued for Debt			840,681
The accompanying Notes are an integral part of these Financial Statements

Entest Group, Inc. (FKA Entest Biomedical, Inc.)

14Opinion on the Financial Statements

~~The~~ We have audited the accompanying balance sheet of Entest Group, Inc. (the “Company”) as of August 31, 2018 and the related statements of operations, stockholders’ equity, and cash flows for the year ended August 31, 2018, and the related notes and schedules (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of August 31, 2018, and the results of its operations and its cash flows for the year ended August 31, 2018 in conformity with accounting principles generally accepted in the United States of America.

~~(formerly known~~Basis asfor ~~Entest Biomedical, Inc.)~~Opinion

~~Notes~~ These financial statements are the responsibility of the Company’s management. Our responsibility is to ~~Consolidated~~express ~~Financial~~an ~~Statements~~opinion on the Company’s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (“PCAOB”) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of ~~August~~our 31audits, ~~2018~~we are required to obtain an understanding of internal control over financial reporting, but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

~~NOTE 1~~Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. ~~ORGANIZATION~~ ~~AND~~Such ~~DESCRIPTION~~procedures OFincluded ~~BUSINESS~~examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

~~Entest Biomedical,~~The ~~Inc~~accompanying (financial ~~The~~statements “have been prepared assuming that the Company”) ~~was~~will ~~incorporated~~continue as a going concern. As discussed in Note 4 to the ~~State~~financial ofstatements, ~~Nevada~~the onCompany ~~September~~has 24no revenues, ~~2008~~has asnegative JBworking ~~Clothing~~capital ~~Corporation. Until~~at ~~July~~August 1031, ~~2009~~2018, ~~the~~has ~~Company~~incurred recurring losses and recurring negative cash flow from operating activities, and has an accumulated deficit which raises substantial doubt about its ability to continue as a going concern. Management’s ~~principal~~plans ~~business~~concerning ~~objective~~these ~~was~~matters are also described in Note 4. The financial statements do not include any adjustments that might result from the ~~offering~~outcome of ~~active/leisure~~this ~~fashion design clothing~~uncertainty.

~~On July 10, 2009 the Company abandoned its efforts in the field of active~~/~~leisure~~s/ ~~fashion~~AMC ~~design clothing when it acquired 100% of the share capital of Entest BioMedical, Inc., a California corporation, (“Entest CA”).~~Auditing

~~On June~~AMC ~~18, 2015 the Company formed Zander Therapeutics, Inc. (“Zander”) , a Nevada corporation. As of August 31, 2018 Entest owns Zander 34.82% of Zander.~~Auditing

~~On February~~We ~~12,~~have ~~2018~~served as the Company’s ~~changed~~auditor ~~its~~since ~~name~~2012 ~~to The Entest Group, Inc.~~

~~As of~~Las ~~August 31~~Vegas, ~~2018 the Company is a “Shell Company” as such term is defined in Rule 12(b)(2) promulgated under the Securities and Exchange Act of 1934 . This Rule defines as Shell Company as a company that has:~~Nevada

~~(1) No~~November or19, ~~nominal operations; and~~2018

~~(2) Either:~~F-3 Table of Contents

~~(i) No~~ENTEST orGROUP, ~~nominal assets;~~INC.

~~(ii) Assets~~Balance ~~consisting solely of cash and cash equivalents; or~~Sheets

(iii) Assets consisting of any amount of cash and cash equivalents and nominal other assets.

	August 31,			August 31,
	2019			2018
Assets
Current Assets
Cash	$	-		$	267
Accrued Interest Receivable		-			1,040
Prepaid expenses		-			8,000
Total Current Assets		-			9,307

Total Assets	$	-		$	9,307

Liabilities And Stockholders' Deficit
Current Liabilities
Accounts payable and accrued expenses	$	11,474		$	218,417
Unearned rental income		-			17,000
Due to related party		21,197			-
Note payable		-			19,601
Total Current Liabilities		32,671			255,018

Total Liabilities		32,671			255,018

Stockholders' Deficit
Preferred stock: 5,000,000 shares authorized; $0.0001 par value:
Series AA Preferred stock: 100,000 shares designated; $0.0001 par value; 667 shares issued and outstanding		-			-
Series AAA Preferred stock: 300,000 shares designated; $0.0001 par value; 534 shares issued and outstanding		-			-
Series B Preferred stock: 4,400,000 shares designated; $0.0001 par value; 728,073 shares issued and outstanding		73			73
Non-Voting Convertible Preferred stock: 3,000,000 shares authorized; $1.00 par value; 1,001,533 shares issued and outstanding		1,001,533			1,001,533
Common stock: 500,000,000 shares authorized; $0.0001 par value; 49,171,083 shares issued and outstanding		4,917			4,917
Additional paid in capital		9,025,314			9,003,892
Accumulated deficit		(10,064,508	)		(10,256,126	)
Total Stockholders' Deficit		(32,671	)		(245,711	)
Total liabilities and Stockholder's Deficit	$	-		$	9,307

~~NOTE 2. SUMMARY~~The OFaccompanying ~~SIGNIFICANT~~Notes ~~ACCOUNTING~~are ~~POLICIES~~an integral part of these audited financial statements.

~~A. BASIS~~F-4 OFTable ~~ACCOUNTING~~of Contents

~~The financial~~ENTEST ~~statements have been prepared using the basis of accounting generally accepted in the United States of America. Under this basis of accounting~~GROUP, ~~revenues are recorded as earned and expenses are recorded at the time liabilities are incurred~~INC. The Company has adopted an August 31 fiscal year-end. The Company recognizes revenue from services and product sales when the following four revenue recognition criteria are met: persuasive evidence of an arrangement exists, delivery has occurred or services have been rendered, the selling price is fixed or determinable, and collectability is reasonably assured.

~~B. PRINCIPLES~~Statements OFof ~~CONSOLIDATION~~Operations

The consolidated financial statements include the accounts of Entest CA, the Company’s wholly owned subsidiary. These financial statement also include the accounts of Zander up to June 10, 2018. Significant inter-company transactions have been eliminated.

	For the
	Years Ended
	August 31,
	2019			2018

Revenue	$	-		$	-

Operating Expenses:
Research and development		-			949,584
Professional fees		22,689			310,020
General and administration		17,429			261,295
Total operating expenses		40,118			1,520,899

Operating Loss		(40,118	)		(1,520,899	)

Other Income (Expense):
Rental income		22,000			66,000
Gain on write off of accounts payable		23,629			-
Write off accrued interest receivable		(1,040	)		-
Gain on deconsolidation of Zander		-			10,034
Equity in losses of Zander		-			(61,428	)
Gain on disposition of Zander		188,589			-
Gain on sale of securities		-			30,000
Interest Income		-			132
Loss on disposition Entest Biomedical		(947	)		-
Interest expense		(495	)		(1,323	)
Total Other Income (Expense)		231,736			43,415

Net Income (Loss) Before Income Tax		191,618			(1,477,484	)

Income tax provision		-			-
Net Income (Loss)	$	191,618		$	(1,477,484	)

Basic income (loss) per common share	$	0.00		$	(0.03	)
Diluted income (loss) per common share	$	0.00		$	(0.03	)

Weighted average number of common shares outstanding
Basic		49,170,472			48,987,813
Diluted		120,708,543			48,987,813

~~C. USE~~The OFaccompanying ~~ESTIMATES~~Notes are an integral part of these audited financial statements.

~~The preparation~~F-5 ofTable ~~financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts~~ of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.Contents

15ENTEST GROUP, INC. Statements of Changes in Stockholders' Deficit For the Year Ended August 31, 2019 and 2018

D. CASH EQUIVALENTS


	Series AA Preferred				Series AAA Preferred				Series B Preferred				Non Voting Convertible Preferred						Common Stock				Additional Paid-in		Accumulated			Accumulated Other Comprehensive			Non Controlling Interest In
	Shares		Amount		Shares		Amount		Shares		Amount		Shares			Amount			Shares		Amount		Capital		Deficit			Income			Subsidiary			Total
Balance August 31, 2017		667	$	-		534	$	-		728,073	$	73		1,026,533		$	1,026,533			46,671,083	$	4,667	$	7,465,656	$	(8,721,496	)	$	185,050		$	56,343		$	16,826

Common Shares issued for conversion of Non-Voting Convertible Preferred Shares		-		-		-		-		-		-		(25,000	)		(25,000	)		2,500,000		250		24,750		-			-			-			-
Common Shares of subsidiary issued for cash		-		-		-		-		-		-		-			-			-		-		1,400,000		-			-			-			1,400,000
Declaration and payment of property dividend		-		-		-		-		-		-		-			-			-		-		57,143		(57,143	)		-			-			-
Non controlling interest in subsidiary		-		-		-		-		-		-		-			-			-		-		56,343		-			-			(56,343	)		-
Accumlated other comprehensive loss		-		-		-		-		-		-		-			-			-		-		-		-			(185,050	)		-			(185,050	)
Net loss for the year		-		-		-		-		-		-		-			-			-		-		-		(1,477,487	)		-			-			(1,477,487	)
Balance August 31, 2018		667	$	-		534	$	-		728,073	$	73		1,001,533		$	1,001,533			49,171,083	$	4,917	$	9,003,892	$	(10,256,126	)	$	-		$	-		$	(245,711	)

Contributed Capital		-		-		-		-		-		-		-			-			-		-		21,422		-			-			-			21,422
Net income for the year		-		-		-		-		-		-		-			-			-		-		-		191,618			-			-			191,618
Balance August 31,2019		667	$	-		534	$	-		728,073	$	73		1,001,533		$	1,001,533			49,171,083	$	4,917	$	9,025,314	$	(10,064,508	)	$	-		$	-		$	(32,671	)

The ~~Company~~ ~~considers~~accompanying ~~all~~Notes ~~highly~~are ~~liquid~~an ~~investments~~integral ~~with~~part ~~a maturity~~ of ~~three~~these ~~months~~audited orfinancial ~~less when purchased to be cash equivalents.~~statement

~~E. PROPERTY~~F-6 ~~AND~~Table ~~EQUIPMENT~~of Contents

~~As of~~ENTEST ~~August 31~~GROUP, ~~2018 Property and Equipment consists of $0~~INC.

~~F. FAIR~~Statements ~~VALUE~~of OFCash ~~FINANCIAL INSTRUMENTS~~Flows

Fair value is the price that would be received for an asset or the exit price that would be paid to transfer a liability in the principal or most advantageous market in an orderly transaction between market participants on the measurement date. A fair value hierarchy requires an entity to maximize the use of observable inputs, where available. The following summarizes the three levels of inputs required by the standard that the Company uses to measure fair value:

	For the
	Year Ended
	August 31,
	2019			2018

Cash Flows From Operating Activities:
Net income (loss)	$	191,618		$	(1,477,484	)
Adjustments to reconcile net income (loss) to net cash used in operating activities:
Gain attributable to deconsolidation		-			(10,034	)
Cash lost in deconsolidation		-			(332,638	)
Equity in losses of Zander		-			61,428
Loss on disposition Entest Biomedical		947			-
Gain on write off of accounts payable		(23,629	)		-
Gain on disposition of Zander		(188,589	)		-
Shareholder advances for operating expense		21,197			-
Changes in operating assets and liabilities:
Accrued interest receivable		1,040			(132	)
Prepaid expenses		8,000			(117,388	)
Accrued rental income receivable		(6,000	)		-
Accounts payable and accrued expenses		(813	)		369,147
Unearned rental income		(7,730	)		17,000
Net Cash Used In Operating Activities		(3,959	)		(1,490,101	)

CASH FLOWS FROM INVESTING ACTIVITIES:
Net cash received for divestiture of Entest Biomedical		1,937			-
Gain on sale of securities received prior to deconsolidation					(2,357	)
Net Cash Provided (Used) by Investing Activities		1,937			(2,357	)

Cash Flows From Financing Activities:
Contributed capital		1,821			-
Proceeds from common stock issued from subsidiary		-			1,400,000
Proceed from bank overdraft		-			66
Repayment of bank overdraft		(66	)
Proceed from notes payable		-			6,100
Net Cash Provided by Financing Activities		1,755			1,406,166

Net Change in Cash		(267	)		(86,292	)
Cash at Beginning of Period		267			86,559
Cash at End of Period	$	0		$	267

Supplemental Cash Flow Information:
Cash paid for interest	$	-		$	-
Cash paid for taxes	$	-		$	-

Supplemental disclosure of non-cash financing activity
Debt Satisfied through Contributed Capital	$	19,601		$	-

~~Level 1: Quoted~~The ~~prices~~accompanying inNotes ~~active~~are ~~markets~~an ~~for~~integral ~~identical~~part ~~assets~~of orthese ~~liabilities~~audited financial statement

~~Level 2: Observable~~F-7 ~~inputs~~Table other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of ~~the related assets or liabilities.~~Contents

~~Level 3: Unobservable~~ENTEST ~~inputs~~GROUP, ~~that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities~~INC.

~~The Company’s financial instruments as of August 31, 2018 consisted of $ 19,601 of~~ Notes ~~Payable and $8,000 due~~ to ~~TheraCyte, Inc..~~Financial The fair value of all of the Company’s financial instruments as of August 31, 2018 were valued according to the Level 3 input. The carrying amount of the financial instruments is equal to the fair value as determined by the Company.Statements

~~The Company~~August ~~has~~31, ~~determined~~2019, ~~that there are no Level 1 or Level 2 inputs for determining the fair value of the Company’s financial instruments. Fair value was determined by the Company utilizing its own assumptions~~ and ~~estimation. There were no transfers between levels for the period presented.~~2018

GNOTE 1. ~~INCOME~~ ORGANIZATION, ~~TAXES~~DESCRIPTION OF BUSINESS, AND GOING CONCERN

~~The Company~~Entest ~~accounts~~Group, ~~for~~Inc. ~~income taxes using~~ (the ~~liability~~“Company” ~~method~~or ~~prescribed by ASC 740,~~ “ ~~Income Taxes.~~ Entest” ~~Under~~) ~~this~~was ~~method,~~incorporated ~~deferred~~in ~~tax assets and liabilities are determined based on~~ the ~~difference~~State ~~between the financial reporting and tax bases~~ of ~~assets~~Nevada ~~and~~on ~~liabilities~~September ~~using~~24, ~~enacted~~2008 ~~tax~~as ~~rates~~JB ~~that~~Clothing ~~will~~Corporation. beOn inJuly ~~effect~~12, in2009, the ~~year in which the differences are expected to reverse. The~~ Company ~~records~~changed aits ~~valuation~~name ~~allowance~~ to ~~offset~~Entest ~~deferred tax assets if based on the weight of available evidence~~BioMedical, itInc. isOn ~~more-likely-than-not~~February ~~that some portion~~12, or2018 ~~all, of~~ the ~~deferred~~Company ~~tax~~changed ~~assets~~its ~~will~~name ~~not~~from beEntest ~~realized~~BioMedical, Inc. ~~The~~to ~~effect~~Entest ~~on deferred~~Group, ~~taxes of a change in tax rates is recognized as income or loss in the period that includes the enactment date~~Inc.

The Company’s ~~applied~~current ~~the~~business ~~provisions~~strategy ofis ~~ASC 740-10-50, “Accounting for Uncertainty in Income Taxes”, which provides clarification related~~ to ~~the~~acquire ~~process~~an ~~associated~~operating ~~with~~company ~~accounting~~seeking ~~for uncertain tax positions recognized in our financial statements. Audit periods remain open for review until~~ the ~~statute~~perceived ofadvantages ~~limitations has passed. The completion~~ of ~~review~~being ora ~~the~~publicly ~~expiration~~held ofcorporation. ~~the~~No ~~statute of~~assurance ~~limitations~~can ~~for~~be a given ~~audit~~that ~~period~~such ~~could result in~~ an ~~adjustment~~acquisition toshall ~~the~~occur ~~Company’s~~or, ~~liability~~if ~~for income taxes. Any~~ such ~~adjustment~~ ~~could~~an beacquisition ~~material~~were to ~~the Company’s results of operations for any given quarterly or annual period based~~occur, init ~~part, upon~~would ~~the~~occur ~~results~~on ofterms ~~operations~~and ~~for~~conditions ~~the~~beneficial ~~given~~to ~~period. As of August 31, 2018~~ the Company ~~had~~or noits ~~uncertain tax positions, and will continue to evaluate for uncertain positions in the future~~shareholders.

16Change of Control

~~The Company~~On ~~generated~~November a15, ~~deferred~~2018, ~~tax~~David ~~credit~~Koos, ~~through~~Regen ~~net~~BioPharma ~~operating~~Inc., ~~loss~~Bostonia ~~carry~~Partners ~~forward~~Inc. ~~However~~, Sherman Family Trust, Dunhill Ross Partners Inc., Bio-Technology Partners Business Trust (collectively, the “Sellers”) and Peiwen Yu (the “Buyer”) entered into a ~~valuation~~stock ~~allowance~~purchase agreement (the “SPA”), pursuant to which the Sellers agreed to sell and the Buyer agreed to purchase an aggregate of ~~100% has~~23,733,334 ~~been~~shares ~~established~~of common stock, 667 shares of Series AA preferred stock, 534 shares of Series AAA preferred stock and 1,001,533 shares of Non-Voting Preferred Stock of Entest from the Seller for an aggregate purchase price of $325,000. The closing of the transactions contemplated by the SPA occurred on November 27, 2018. The purchase price was paid out of the Buyer’s personal funds.

~~Interest~~ As of the date of the transaction, Entest had 49,170,472 shares of common stock, 728,073 shares of Series B Preferred Stock, 667 shares of Series AA Preferred Stock, 534 shares of Series AAA Preferred Stock and ~~penalties~~1,001,533 onshares ~~tax~~of ~~deficiencies~~Non-Voting ~~recognized~~Convertible inPreferred ~~accordance~~Stock ~~with~~outstanding. ~~ACS~~The ~~accounting~~securities ~~standards~~purchased ~~are~~pursuant ~~classified~~to asthe ~~income~~SPA ~~taxes~~represent in48.3% ~~accordance with~~of ~~ASC~~the ~~Topic~~outstanding ~~740~~shares of common stock, 90% of the outstanding shares of common stock assuming the conversion of the Non-~~10-50-19~~Voting Convertible Preferred Stock on the execution date of the SPA and 94% of the voting power of Entest.

HAs contemplated by the SPA, in November 2018, David Koos resigned as Chairman, Chief Executive Officer, President, Acting Chief Financial Officer and Secretary of Entest and Peiwen Yu became as a director, Chief Executive Officer and President of Entest. ~~BASIC~~ ~~EARNINGS~~Pursuant to the SPA, in November 2018, Mr. Koos also resigned as a director of the Company upon compliance by Entest with information statement delivery requirements pursuant to Rule 14f-1 under the Securities Exchange Act of 1934, as amended (~~LOSS)~~the ~~PER~~“Exchange ~~SHARE~~Act”).

~~The Financial~~Going ~~Accounting~~Concern ~~Standards Board (FASB) issued Accounting Standards Codification (ASC) 260, "Earnings Per Share", which specifies the computation, presentation~~ and ~~disclosure~~Liquidity requirements for earnings (loss) per share for entities with publicly held common stock. ASC 260 requires the presentation of basic earnings (loss) per share and diluted earnings (loss) per share. The Company has adopted the provisions of ASC 260 effective from inception. Basic net loss per share amounts is computed by dividing the net income by the weighted average number of common shares outstanding. All convertible debt has an anti-dilutive effect on the EPS, therefore Diluted earnings per share are the same as basic earnings per share.Considerations

~~NOTE 3~~The accompanying audited financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. ~~RECENT~~ ~~ACCOUNTING~~The ~~PRONOUNCEMENTS~~Company has not generated any revenues since the change of control and disposition of its subsidiaries and has an accumulated deficit of $10,064,508. These factors among others raise substantial doubt about the ability of the Company to continue as a going concern for a reasonable period. The accompanying financial statements do not include any adjustments that might result from the outcome of this uncertainty.

~~In June~~The ~~2014,~~continuing ~~the~~operations ~~Financial Accounting Standards Board issued Accounting Standards Update No. 2014-10, which eliminated certain financial reporting requirements~~ of ~~companies~~the ~~previously~~Company ~~identified~~are asdependent ~~"Development~~upon ~~Stage~~its ~~Entities"~~ability ~~(Topic~~to ~~915).~~continue ~~The~~to ~~amendments in~~raise ~~this~~adequate ~~ASU~~financing ~~simplify accounting guidance by removing all incremental financial reporting requirements for development stage entities. The amendments also reduce data maintenance~~ and, ~~for those entities subject~~ to ~~audit,~~commence ~~audit~~profitable ~~costs~~operations ~~by eliminating the requirement for development stage entities to present inception-to-date information~~ in the ~~statements~~future ~~of income, cash flows,~~ and ~~shareholder equity.~~repay ~~Early~~its ~~application~~liabilities ofarising ~~each~~from ofnormal ~~the amendments is permitted for any annual reporting period or interim period for which the entity's financial statements have not yet been issued (public~~ business ~~entities)~~operations oras ~~made~~they ~~available~~become ~~for issuance (other entities)~~due. ~~Upon adoption, entities will no longer present or disclose any information required by Topic 915. The Company has adopted this standard.~~

~~The following~~In ~~accounting~~support ~~standards~~of ~~updates~~the ~~were~~Company’s ~~recently~~efforts ~~issued~~ and ~~have~~cash ~~not~~requirements, ~~yet~~it ~~been~~may ~~adopted~~rely byon ~~the~~advances ~~Company.~~from ~~These~~related ~~standards~~parties ~~are currently~~until ~~under~~such ~~review~~time tothat ~~determine~~the ~~their~~Company ~~impact~~can onsupport ~~the~~its ~~Company’s~~operations ~~consolidated~~or ~~financial~~attains ~~position,~~adequate ~~results~~financing through sales of ~~operations,~~ its equity or ~~cash~~traditional ~~flows~~debt financing. There is no formal written commitment for continued support by shareholders or directors.

~~In May 2014, FASB issued Accounting Standards Update (ASU) No. 2014~~F-~~09,~~8 ~~Revenue~~Table from Contracts with Customers. The revenue recognition standard affects all entities that have contracts with customers, except for certain items. The new revenue recognition standard eliminates the transaction-and industry-specific revenue recognition guidance under current GAAP and replaces it with a principle-based approach for determining revenue recognition. Public entities are required to adopt the revenue recognition standard for reporting periods beginning after December 15, 2016, and interim and annual reporting periods thereafter. Early adoption is not permitted for public entities. The Company has reviewed the applicable ASU and has not, at the current time, quantified the effects of ~~this pronouncement, however it believes that there will be no material effect on the consolidated financial statements.~~Contents

~~In June~~NOTE ~~2014, FASB issued Accounting Standards Update (ASU) No~~2. SUMMARY ~~2014-12~~OF ~~Compensation~~SIGNIFICANT —ACCOUNTING Stock Compensation (Topic 718), Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period. A performance target in a share-based payment that affects vesting and that could be achieved after the requisite service period should be accounted for as a performance condition under Accounting Standards Codification (ASC) 718, Compensation — Stock Compensation. As a result, the target is not reflected in the estimation of the award's grant date fair value. Compensation cost would be recognized over the required service period, if it is probable that the performance condition will be achieved. The guidance is effective for annual periods beginning after 15 December 2015 and interim periods within those annual periods. Early adoption is permitted. The Company has reviewed the applicable ASU and has not, at the current time, quantified the effects of this pronouncement, however it believes that there will be no material effect on the consolidated financial statements.POLICIES

17Basis of Presentation

~~In August2014,~~The ~~FASB~~audited ~~issued~~financial ~~Accounting~~statements ~~Standards~~have ~~Update~~been ~~(ASU)~~prepared ~~No.~~and ~~2014-15~~presented ~~Preparation~~in ofconformity ~~Financial~~with ~~Statements~~accounting –principles ~~Going~~generally ~~Concern (Subtopic~~accepted ~~205-40),~~in ~~Disclosure~~the ofUnited ~~Uncertainties~~States ~~about an Entity's Ability to Continue as a Going Concern. Under generally accepted accounting principles~~ (“GAAP”), ~~continuation~~applicable ofto aannual ~~reporting entity as a going concern is presumed as the basis for preparing~~ financial ~~statements~~ ~~unless~~information and ~~until~~with the ~~entity's~~instructions ~~liquidation becomes imminent. Preparation of financial statements under this presumption is commonly referred~~ to asForm ~~the~~10-K ~~going concern basis of accounting. If~~ and ~~when~~regulation ~~an entity's liquidation becomes imminent, financial statements should be prepared under the liquidation basis~~ of accounting in accordance with Subtopic 205-30, Presentation of Financial Statements—Liquidation Basis of Accounting. Even when an entity's liquidation is not imminent, there may be conditions or events that raise substantial doubt about the ~~entity's~~Securities ~~ability~~and toExchange ~~continue~~Commission ~~as a going concern~~(“SEC”). InThe ~~those~~annual ~~situations,~~ financial ~~statements~~ ~~should~~information ~~continue~~has tobeen be prepared ~~under~~on ~~the~~a ~~going concern~~ basis ofconsistent ~~accounting,~~with ~~but~~prior ~~the~~years ~~amendments in this Update should be followed to determine whether to disclose information about the relevant conditions~~ and ~~events.~~includes ~~The~~all ~~amendments~~disclosures inthat ~~this Update~~ are ~~effective~~necessary ~~for~~and ~~the~~required ~~annual~~by ~~period~~applicable ~~ending~~laws ~~after December 15, 2016,~~ and ~~for annual periods and interim periods thereafter~~regulations. Early application is permitted. The Company will evaluate the going concern considerations in this ASU, however, at the current period, management does not believe that it has met the conditions which would subject these financial statements for additional disclosure.

~~NOTE 4~~The audited financial statements and notes are presented in accordance with accounting principles generally accepted in the United States of America (GAAP) and are presented in U. ~~GOING~~S. ~~CONCERN~~dollars. These annual financial statements include all adjustments that, in the opinion of management, are necessary in order to make the financial statements not misleading.

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. The Company generated net losses of $10,256,126 during the period from August 22, 2008 (inception) through August 31, 2018. This condition raises substantial doubt about the Company's ability to continue as a going concern. The Company's continuation as a going concern is dependent on its ability to meet its obligations, to obtain additional financing as may be required and ultimately to attain profitability. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.Reclassifications

~~Management intends~~Certain toprior ~~seek~~year ~~business~~amounts ~~opportunities~~have tobeen ~~review~~reclassified ~~and~~to ~~analyze~~conform ~~for purposes of effecting a merger, acquisition or other business combination~~ with anthe ~~operating~~current ~~company~~year ~~business~~presentation.

~~NOTE 5. NOTES~~Basis ~~PAYABLE~~ of Consolidation

~~As of~~The consolidated financial statements for the year ended August 31, 2018, include the accounts of Entest CA, the Company’s wholly owned subsidiary. These financial statements also include the accounts of Zander up to June 10, 2018. Significant inter-company transactions have been eliminated. During the year ended August 31, 2019, the entities were deconsolidated (see Notes 3, 5 and 6).

~~Notes Payable:~~Use of Estimates

David Koos (See Note 6)	$	2,600
Dunhill Ross Partners, Inc.	$	850
Blackbriar Partners (See Note 6)		11,600
Regen Biopharma, Inc (See Note 6)		4,551
Total	$	19,601

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements. The estimates and judgments will also affect the reported amounts for certain revenues and expenses during the reporting period. Actual results could differ from these good faith estimates and judgments.

~~$1,000 lent~~ Cash ~~to the Company by Blackbriar Partners is due~~ and ~~payable~~Cash ~~February 17, 2018 and bears simple interest at a rate of 10% per annum~~Equivalents

~~$7,000 lent~~Cash toand ~~the~~cash ~~Company~~equivalents byinclude ~~Blackbriar~~cash ~~Partners~~in ishand ~~due~~ and ~~payable~~cash ~~February~~in 28time deposits, ~~2018~~certificates of deposit and ~~bears~~all ~~simple~~highly ~~interest~~liquid atdebt ainstruments ~~rate~~with original maturities of ~~10%~~three ~~per annum~~months or less. The Company had $0 and $267 in cash at August 31, 2019 and 2018, respectively.

~~$3,000 lent~~Fair toValue ~~the Company by Blackbriar Partners is due and payable May 4, 2019 and bears simple interest at a rate of 10% per annum.~~Measurements

~~$600 lent~~As defined in ASC 820” Fair Value Measurements,” fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). The Company byutilizes ~~Blackbriar~~market ~~Partners~~data isor ~~due~~assumptions ~~and~~that ~~payable~~market ~~August~~participants 20would use in pricing the asset or liability, ~~2019~~including assumptions about risk and ~~bears~~the ~~simple~~risks ~~interest~~inherent atin athe ~~rate~~inputs to the valuation technique. These inputs can be readily observable, market corroborated, or generally unobservable. The Company classifies fair value balances based on the observability of ~~10%~~those ~~per~~inputs. ~~annum~~ASC 820 establishes a fair value hierarchy that prioritizes the inputs used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurement) and the lowest priority to unobservable inputs (level 3 measurement).

~~Blackbriar Partners~~The isCompany's ~~controlled~~financial byinstruments ~~David~~consist R.of ~~Koos~~interest receivable, ~~the~~accounts ~~Company’s~~payable, ~~sole~~and ~~officer~~due ~~and~~to ~~director~~related parties. The carrying amounts of these financial instruments approximate fair value due to either length of maturity or interest rates that approximate prevailing rates unless otherwise disclosed in these financial statements.

18F-9 Table of Contents

~~As of~~Income August 31, 2018 the Company remains indebted to David R. Koos , the Company’s sole officer and director, in the principal amount of $2,600 due and payable in whole or in part at the demand of David Koos and bearing simple interest at a rate of 15% per annum.Taxes

~~Amounts due~~Income totaxes ~~Regen~~are ~~Biopharma~~accounted ~~Inc~~for under the asset and liability method. asDeferred oftax ~~August~~assets ~~31,~~and ~~2018~~liabilities are ~~due~~recognized ~~and~~for ~~payable~~the atfuture tax consequences attributable to differences between the ~~demand~~financial statement carrying amounts of ~~the~~existing ~~holder~~assets and ~~bear~~liabilities ~~simple~~and ~~interest~~their ~~at a~~respective ~~rate~~tax ofbases ~~10%~~and ~~per~~operating ~~annum~~loss and tax credit carry forwards. ~~David~~Deferred Rtax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. ~~Koos~~The ,effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is recorded to reduce the Company’s ~~sole~~deferred ~~officer,~~tax ~~serves~~assets asto ~~Chairman~~the ~~and~~amount ~~Chief~~that ~~Executive~~is ~~officer~~more oflikely ~~Regen Biopharma,~~than ~~Inc~~not to be realized.

~~NOTE 6. RELATED~~Basic ~~PARTY~~and ~~TRANSACTIONS~~Diluted Net Income (Loss) per Common Share

~~As of~~We ~~August~~compute 31basic and diluted earnings (loss) per share amounts in accordance with ASC Topic 260, ~~2018~~“Earnings ~~the~~per ~~Company~~Share.” ~~remains~~Basic ~~indebted~~earnings (loss) per share is computed by dividing net income (loss) available to ~~David~~common R.shareholders ~~Koos~~by ,the weighted average number of common shares outstanding during the ~~Company’s~~reporting ~~sole~~period. ~~officer~~Diluted ~~and~~earnings ~~director,~~(loss) inper share reflects the ~~principal amount~~potential ofdilution ~~$2,600~~that ~~due~~could occur if stock options and ~~payable~~other incommitments ~~whole~~to issue common stock were exercised or inequity ~~part~~awards atvest resulting in the ~~demand~~issuance of ~~David~~common ~~Koos~~stock ~~and~~that ~~bearing~~could ~~simple~~share ~~interest~~in atthe aearnings ~~rate~~ of ~~15% per~~the ~~annum~~Company.

~~As of~~For ~~August 31, 2018~~ the ~~Company~~year ~~remains~~ended ~~indebted~~August ~~to Blackbriar Partners in the principal amount of $11~~31,~~600~~ of2019 ~~which $1,000 is due~~ and ~~payable February 17,~~ 2018 ~~and bears simple interest at a rate of 10%per annum and of which $7~~,~~000~~ ~~is due and payable February 28~~respectively, ~~2018~~the ~~and~~following ~~bears~~common ~~simple~~stock ~~interest~~equivalents atwere apotentially rate of 10% per annum , of which$3,000 is due and payable May 4, 2019 and bears simple interest at a rate of 10% per annum and of which $600 is due and payable August 20, 2019 and bears simple interest at a rate of 10% per annumdilutive.

Blackbriar Partners is controlled by David R. Koos , the Company’s sole officer and director.

	Years ended August 31,
	2019		2018
	(Shares)		(Shares)
Non-Voting Convertible Preferred Stock		71,538,071		96,807,783

~~As of~~For ~~August 31, 2018~~ the ~~Company~~year ~~remains~~ended ~~indebted~~August to31, ~~Regen Biopharma~~2018, ~~Inc.~~we inexcluded the ~~principal~~computation ~~amount~~ of ~~$4,551~~diluted ~~due~~net ~~and~~loss ~~payable~~per ~~in whole~~share oras ~~in part at~~ the ~~demand~~result of the ~~holder~~computation ~~and~~was ~~bearing~~anti-dilutive, ~~simple~~therefore, ~~interest~~the atdiluted aloss ~~rate of 10%~~ per ~~annum.~~share ~~David~~is ~~R. Koos ,~~ the ~~Company’s sole~~same ~~officer, serves~~ as ~~Chairman~~basic ~~and~~loss ~~Chief~~per ~~Executive officer of Regen Biopharma, Inc~~share.

~~On October~~Recent 1,Accounting 2014 Regen Biopharma Inc. entered into an agreement to sublease approximately 2,320 square feet of office space from the Company. Entest Biomedical Inc. is under common control with Regen Biopharma, Inc. as the Chairman and CEO of the Company also serves as the Chairman and CEO of Regen Biopharma, Inc. The sublease is on a month to month basis and rent payable to the Company by Regen Biopharma Inc is equal to the rent payable to the lessor by the Company and is to be paid in at such time specified in accordance with the original lease agreement between the Company and the lessor. On January 20, 2015 the sublease was amended retroactive to January 1, 2015 as follows:Pronouncements

~~The rent~~In ~~payable~~February to2016, ~~Entest~~the ~~BioMedical,~~FASB ~~Inc~~issued ASU No. by2016-02 ~~the~~(Topic ~~subtenant~~842) is"Leases." ~~equal~~Topic to842 ~~Five~~supersedes ~~Thousand~~the ~~Dollars~~lease ~~per~~recognition ~~month~~requirements in Accounting Standards Codification (~~$5,000~~“ASC”) ~~and~~Topic is840 to"Leases." beUnder ~~paid in~~Topic at842, ~~such~~lessees ~~time~~are ~~specified~~required into ~~accordance~~recognize ~~with~~assets and liabilities on the ~~original~~balance ~~lease~~sheet ~~agreement~~for ~~between~~most ~~the~~leases ~~Entest~~and ~~BioMedical,~~provide ~~Inc~~enhanced disclosures. ~~(“Entest”) and~~Leases ~~the~~will ~~lessor~~continue to be classified as either finance or operating. ~~All~~Topic ~~charges~~842 is effective for ~~utilities~~annual ~~connected~~reporting ~~with~~periods ~~premises~~and ~~which~~interim ~~are~~periods towithin bethose ~~paid~~years ~~under~~beginning ~~the~~after ~~master~~15 ~~lease~~December ~~shall~~2018. beEarly ~~paid~~adoption by ~~Regen~~ ~~Biopharma,~~public ~~Inc~~entities is permitted. ~~for~~Entities ~~the~~are ~~term~~required ofto ~~this~~use ~~sublease~~a tomodified ~~the~~retrospective ~~extent~~approach for leases that ~~such~~exist ~~charges~~or ~~exceed~~are ~~the~~entered ~~difference~~into ~~between~~after the ~~rent~~beginning ~~payable to~~of the ~~lessor~~earliest bycomparative ~~Entest~~period ~~under~~in the ~~master~~financial ~~lease~~statements, and ~~the~~there ~~rent~~are ~~payable~~certain optional practical expedients that an entity may elect to ~~Entest~~apply. byFull ~~Regen~~retrospective ~~Biopharma,~~application ~~Inc~~is prohibited. The Company does not anticipate this amendment to have a significant impact on the financial statements.

19In June 2016, the FASB issued ASU No. 2016-13 "Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments" which requires the measurement and recognition of expected credit losses for financial assets held at amortized cost. ASU 2016-13 replaces the existing incurred loss impairment model with an expected loss methodology, which will result in more timely recognition of credit losses. ASU 2016-13 is effective for annual reporting periods, and interim periods within those years beginning after 15 December 2019. The Company does not anticipate this amendment to have a significant impact on the financial statements.

~~On February~~F-10 ~~28,~~Table ~~2016, the Company purchased from a third party 3,500,000 shares~~ of the Series A Preferred stock of Regen Biopharma, Inc for consideration consisting of $5,000 cash and 500,000 shares of the Company’s Series B Preferred Stock. On July 3, 2018 the Company sold the aforementioned 3,500,000 shares to Zander for consideration consisting of $35,000. David R. Koos, who serves as Chairman and Chief Executive Officer of Zander also serves as Chairman and Chief Executive Officer of Entest. Zander is under common control with Entest.Contents

~~On July~~In 3February 2018, the FASB issued ASU No. 2018-02, ~~Zander~~“Income ~~entered~~Statement—Reporting ~~into~~Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income”. The amendments in this ASU address a ~~sublease~~narrow-scope ~~agreement~~financial ~~with~~reporting ~~Entest~~issue ~~whereby~~related ~~Zander~~to ~~would~~the ~~sublet~~tax ~~office~~effects ~~space~~that ~~located~~may atbecome ~~4700~~“stranded” ~~Spring Street~~in accumulated other comprehensive income (AOCI) as a result of the Tax Cuts and Jobs Act (TCJA). The amendments in ASU 2018-02 are effective for all entities for fiscal years beginning after 15 December 2018, ~~Suite~~and ~~304~~interim periods within those fiscal years. Early adoption is permitted, Laincluding ~~Mesa~~adoption in any interim period, ~~California~~(1) ~~91942~~for ~~from~~public ~~Entest~~business onentities afor ~~month~~reporting toperiods ~~month~~for ~~basis~~which financial statements have not yet been issued and (2) for ~~$6,000~~all ~~per~~other ~~month~~entities ~~beginning~~for ~~July~~reporting 5,periods for which financial statements have not yet been made available for issuance. The amendments in ASU 2018-02 should be applied either in the period of adoption or retrospectively to each period (or periods) in which the effect of the change in the U.S. federal corporate income tax rate in the TCJA is recognized. The Company does not anticipate this amendment to have a significant impact on the financial statements.

~~David R.~~In ~~Koos~~August 2018, ~~who~~the ~~serves~~FASB asissued ~~Chairman~~ASU 2018-13, Disclosure Framework –Changes to the Disclosure Requirements for Fair Value Measurement (Topic 820). ASU 2018-13 adds, modifies, and ~~Chief~~removes ~~Executive~~certain ~~Officer~~fair ofvalue ~~Zander~~measurement ~~also~~disclosure ~~serves~~requirements. asASU ~~Chairman~~2018-13 is effective for annual and ~~Chief~~interim ~~Executive~~periods ~~Officer~~beginning ofafter ~~Entest~~December 15, 2019. ~~Zander~~ Early adoption is ~~under~~permitted. ~~common~~The ~~control~~Company ~~with~~is ~~Entest~~currently evaluating the effect of adopting this ASU on the Company’s financial statements.

~~NOTE 7. INCOME~~The ~~TAXES~~Company does not believe other recently issued but not yet effective accounting standards, if currently adopted, would have a material effect on the consolidated financial position, statements of operations and cash flows.

As of August 31, 2018
Deferred tax assets:
Net operating tax carry forwards	$	2,156,652
Other		-0-
Gross deferred tax assets		2,156,652
Valuation allowance		(2,156,652	)
Net deferred tax assets	$	-0-

NOTE 3. RELATED PARTY TRANSACTIONS

~~As of August~~On 31July 3, 2018 ~~the~~, ~~Company~~Zander ~~has~~entered into a ~~Deferred~~sublease ~~Tax~~agreement ~~Asset~~with ofEntest $2whereby Zander would sublet office space located at 4700 Spring Street,~~156~~ Suite 304,~~652~~ ~~completely~~La ~~attributable~~Mesa, toCalifornia ~~net~~91942 ~~operating~~from ~~loss carry~~Entest ~~forwards~~on ofa ~~approximately~~month to month basis for $6,000 10per month beginning July 5,~~269~~ 2018. On November 16,~~773(which~~ ~~expire~~2018 20Zander ~~years~~Therapeutics ~~from~~Inc. and the ~~date~~Company agreed to terminate Zander’s sublease with the ~~loss~~Company effective the rental period commencing November, 2018. David R. Koos, who served as Chairman and Chief Executive Officer of Zander as of that date also served as Chairman and Chief Executive Officer of Entest as of that date. Zander was ~~incurred)~~under ~~consisting~~common control with Entest as of: that date.

~~(a) $~~On 13November 16,~~647~~ 2018, Entest Group, Inc. and its then Chairman and Chief Executive Officer, David R. Koos, agreed to satisfy any and all unpaid interest resulting from accrued interest earned on Notes Payable to Koos by Entest from the beginning of ~~Net~~time ~~Operating~~to ~~Loss~~November ~~carry~~30, ~~forwards~~2018 ~~acquired~~by intransferring to David R. Koos 3,000,000 shares of the ~~reverse~~Series ~~acquisition~~M Preferred stock of ~~Entest~~Zander ~~BioMedical~~Therapeutics, Inc., aowned ~~California~~by ~~corporation, and~~the Company.

Entest Group, Inc. and Blackbriar Partners (b“BP”) $ ~~10,256,126~~agreed ofto ~~Net~~satisfy ~~Operating~~any ~~Loss~~and ~~carry~~all ~~forwards~~unpaid ~~attributable~~interest resulting from accrued interest earned on Notes Payable to BP by Entest ~~BioMedical~~from the Company’s inception to November 30, 2018 by transferring to BP 20,000 shares of the Series M Preferred stock of Zander Therapeutics, Inc. owned by the Company. BP is controlled by David Koos, as of that date, the Company’s then Chairman and Chief Executive Officer.

~~Realization of~~Entest ~~deferred~~Group, ~~tax~~Inc. ~~assets~~and ~~is dependent upon sufficient future taxable income during~~ the ~~period~~Bio ~~that~~Matrix ~~deductible~~Scientific ~~temporary~~Group, ~~differences and~~Inc. ~~carry~~(“BMSN”) ~~forwards~~agreed ~~are expected~~ to besatisfy ~~available~~any toand ~~reduce~~all ~~taxable~~unpaid ~~income.~~interest Aresulting ~~valuation~~from ~~allowance~~accrued isinterest ~~recorded~~earned ~~when~~on itNotes isPayable ~~“more likely-than-not”~~to ~~that~~BMSN aby ~~deferred~~Entest ~~tax~~from ~~asset~~the ~~will~~Company’s ~~not~~inception beto ~~realized.~~November ~~In addition~~30, ~~the~~2018 ~~reverse~~by ~~acquisition~~transferring into ~~which~~BMSN ~~Entest BioMedical~~5, ~~Inc.~~000 ~~was~~shares ~~involved in 2009 has resulted in a change~~ of ~~control. Internal~~the ~~Revenue~~Series ~~Code~~M ~~Sec~~Preferred ~~382~~stock ~~limits the amount~~ of ~~income that~~Zander ~~may~~Therapeutics, beInc. ~~offset~~owned by ~~net~~the ~~operating~~Company. ~~loss~~As ~~(NOL)~~of ~~carryovers~~November ~~after~~16, an2018, ~~ownership~~David ~~change~~R. AsKoos awas ~~result,~~ the ~~Company~~Chairman ~~has~~and ~~recorded~~Chief aExecutive ~~valuation allowance~~Officer ~~reducing~~of ~~all~~the ~~deferred~~Company ~~tax~~and ~~assets to $ -0-~~BMSN.

~~Income tax~~Entest isGroup, ~~calculated~~Inc. atand Regen Biopharma, Inc. (“RGBP”) agreed to satisfy any and all unpaid interest resulting from accrued interest earned on Notes Payable to RGBP by Entest from the ~~21%~~beginning ~~Federal~~of ~~Corporate~~time ~~Rate~~to November 30, 2018 by transferring to RGBP 250,000 shares of the Series M Preferred stock of Zander Therapeutics, Inc. owned by the Company.

~~NOTE 8~~Entest Group, Inc. ~~ACQUISITION~~ OFand ~~ENTEST~~Regen CABiopharma, Inc. (“RGBP”) agreed to satisfy any and all rent prepaid by RGBP to Entest from the beginning of time to November 30, 2018 by transferring to RGBP 475,000 shares of the Series M Preferred stock of Zander Therapeutics, Inc. owned by the Company. As of November 16, 2018, David R. Koos was the Chairman and Chief Executive Officer of the Company and RGBP.

~~On July~~F-11 ~~10,~~Table ~~2009 the Company acquired 100%~~ of Entest CA, a California corporation and wholly owned subsidiary of the Company, from BMSN for consideration consisting of (a) the issuance to BMSN of 10,000,000 newly issued common shares of Entest and (b) the return by Mr. Rick Plote of 10,000,000 shares of Entest’s common stock previously issued to him by Entest for cancellation.Contents

20In November 2018, the Company divested itself of Entest BioMedical, Inc., a California corporation, for consideration consisting of $2,000 paid by an entity controlled by David R. Koos.

~~NOTE 9. ACQUISITION~~The OFCompany ~~THE~~recognized ~~ASSETS~~a OFloss ~~PET~~of ~~POINTERS,~~$947 ~~INC~~on the disposition based on the difference between the Net Assets of the subsidiary and the consideration paid.

~~On January~~During 4,the ~~2011~~year ~~Entest~~ended CAAugust ~~acquired~~31, ~~from~~2019, ~~Pet~~the ~~Pointers,~~Company’s ~~Inc.,~~sole aofficer ~~California~~advanced ~~corporation~~to ~~doing~~the ~~business~~Company asan ~~McDonald~~amount ~~Animal~~of ~~Hospital (“Seller”)~~$21,197 ~~and~~for ~~Dr.~~the ~~Gregory~~payment ~~McDonald~~of ~~DVM~~operating ~~(“McDonald”)~~expenses ~~all~~on ~~the~~behalf ~~goodwill~~of ~~from~~the ~~McDonald~~Company. ~~and~~As ~~assets~~ of ~~Seller except~~August ~~cash~~31, 2019, and ~~accounts~~2018, ~~receivables~~the ~~used~~Company inwas ~~connection~~obligated ~~with~~to the ~~operation~~officer, offor aan ~~veterinary~~unsecured, ~~medical~~non-interest ~~clinic~~bearing ~~located~~demand atloan ~~225~~with S.a ~~Milpas Street,~~balance ~~Santa~~of ~~Barbara~~$21,197 CAand ~~93103~~$0, ~~(the "Business")~~respectively.

~~Consideration for~~NOTE ~~the~~4. ~~acquisition~~STOCKHOLDERS’ ~~consisted of:~~EQUITY

~~I. $70,000~~Authorized ~~in cash~~Stock

~~II.~~ The Company is authorized to issue an aggregate of 500,000,000 shares of common stock with a par value of $~~210~~0.0001, 5,000,000 shares of ~~the~~preferred ~~Company’s~~stock ~~common~~with a par value of $0.0001, and 3,000,000 shares ~~valued~~of atnon-voting ~~the~~convertible ~~closing~~preferred ~~price~~stock ~~per~~with a par value of $1.00. Each share asof common stock entitles the holder to one vote on any matter on which action of ~~January~~the 4,stockholders ~~2011~~of the corporation is sought.

~~III. Payment~~Series ofAA noPreferred ~~more than $78,000 to a creditor of the Seller to be paid in monthly installments of $1,500 per month~~Stock

~~IV. Payment~~The ofCompany nois ~~more~~authorized ~~than~~to ~~$25~~issue 100,000 toshares ~~additional creditors~~ of ~~the~~Series ~~Seller~~AA toPreferred beStock ~~paid~~at ina ~~monthly~~par ~~installments~~value of $~~825~~0.0001 per ~~month~~share.

~~V. Payment~~As of ~~$50~~August 31,~~000~~ to2019, ~~McDonald~~and onAugust ~~the~~31, ~~first~~2018, ~~business~~667 ~~day~~shares of ~~the~~Series ~~fourth~~AA ~~month~~Preferred ~~following~~Stock ~~the~~were ~~closing~~issued ofand ~~the acquisition (“Closing”)~~outstanding.

~~NOTE 10.~~Series ~~DISPOSITION~~B OFPreferred ~~THE ASSETS OF PET POINTERS, INC.~~Stock

~~On November~~The ~~28, 2012 the “~~Company ~~executed~~is anauthorized ~~agreement~~to ~~(“Agreement”)~~issue ~~with Gregory McDonald ("McDonald")~~4, ~~Pet Pointers~~400,000 ~~Inc.~~shares ~~("Pet Pointer") whereby Mc Donald and Pet Pointer would acquire from the Company all assets (with the exception~~ of ~~cash~~Series ~~and~~B ~~accounts~~Preferred ~~receivable)~~Stock ~~utilized~~at bya ~~the~~par ~~Company~~value ~~in the operation~~ of ~~the~~$0.0001 ~~McDonald~~per ~~Animal Hospital, a full service veterinary clinic owned and operated by the Company and located in Santa Barbara, California (“McDonald Asset Sale”)~~share.

~~On October~~As ~~10, 2012 a Complaint (“Complaint”) was filed in the Superior Court~~ of ~~the~~August ~~State of California against the Company and David Koos by McDonald~~31, ~~a former employee of the Company~~2019, ~~alleging breach of contract~~ and ~~breach~~August ~~of the covenant of good faith and dealing in connection with the assumption of lease obligations by the Company in connection with the acquisition of the assets of Pet Pointers~~31, ~~Inc breach of contract and breach of the covenant of good faith and dealing in connection with an employment agreement enters into with McDonald inc connection with the Acquisition~~2018, ~~breach of contract in connection with the Acquisition purchase agreement~~728,073 ~~breach~~shares of ~~the~~Series ~~covenant~~B ofPreferred ~~good~~Stock ~~faith~~were ~~and~~issued ~~dealing in connection with the Acquisition purchase agreement, implied indemnity in connection to amounts owed by McDonald to Anthony~~ and Judi Marinelli, the Internal Revenue Service, and the California Franchise Tax Board, intentional misrepresentation, negligent misrepresentation , failure to pay wages and violations of Sections 2802, 203, and 2806 of the California Labor Codeoutstanding. The Complaint sought judgment for nominal damages, actual damages, compensatory damages, lost wages, compensation, expenses wage benefits and penalties pursuant to California Labor Code Sections 203 et al, 2802 and 2806, indemnification, accrued interest, punitive damages, costs of suit and attorney’s fees.

~~As consideration~~Series toAAA ~~the~~Preferred Company for the assets acquired, McDonald and Pet Pointers provided to the Company a General release whereby McDonald and Pet Pointer waive, release and discharge the Company and their respective assignees, officers, directors, shareholders, boards, owners, employees, attorneys, agents, trustors, trustees, beneficiaries, heirs, successors, and representatives from all known and unknown claims, demands, causes of action, attorney's fees, costs, or expenses including: Stock

21The Company is authorized to issue 300,000 shares of Series AAA Preferred Stock at a par value of $0.0001 per share.

~~(1) All~~As ~~claims~~of ~~relating~~August to31, ~~the~~2019, ~~Complaint~~and August 31, 2018, 534 shares of Series AAA Preferred Stock were issued and outstanding.

~~(2) Those~~Non-Voting ~~owed~~Convertible byPreferred McDonald to Anthony and Judi Marinelli which the Company became obligated to pay on McDonald’s behalf pursuant to the asset purchase agreement entered into between the Company and Gregory McDonald and Pet Pointers, Inc on January 4, 2011.Stock

~~(3) Those~~The ~~amounts owed by McDonald to the Internal Revenue Service which the~~ Company ~~became~~is ~~obligated~~authorized to ~~pay~~issue on3,000,000 ~~McDonald’s~~shares ~~behalf pursuant~~of toNon-Voting ~~the~~Convertible ~~asset~~Preferred ~~purchase~~Stock ~~agreement~~at ~~entered~~a ~~into~~par ~~between~~value ~~the~~of ~~Company~~$1.00 ~~and~~per ~~Gregory McDonald and Pet Pointers, Inc on January 4, 2011~~share.

(On October 2, 2018, the Company amended Article 4~~) Those~~ ~~amounts~~of ~~owed~~its byArticles ~~McDonald~~of Incorporation to change the ~~California~~conversion ~~Franchise~~features ~~Tax~~of ~~Board which~~ the Company’s ~~became~~Non ~~obligated~~-Voting Convertible Preferred Stock. The Conversion Price changed from being equal to ~~pay~~the greater of $0.01 per share or seventy percent (70%) of the lowest closing bid price of its shares of common stock (the “Closing Price”) on ~~McDonald~~its principal trading market or exchange for the five (5) trading days immediately preceding written receipt by the corporation of the holder’s ~~behalf~~ ~~pursuant~~intent to convert to being equal to the ~~asset~~greater ~~purchase~~of ~~agreement~~(i) ~~entered~~$0.001 ~~into~~per ~~between~~share and (ii) seventy percent (70%) of the ~~Company~~lowest ~~and~~Closing ~~Gregory~~Price ~~McDonald~~for ~~and~~the ~~Pet~~five ~~Pointers,~~(5) ~~Inc~~trading ~~on January~~days 4,immediately ~~2011~~preceding written receipt by the corporation of the holder’s intent to convert.

~~Assets disposed~~As of ~~pursuant~~August to31, ~~the~~2019, ~~Agreement~~and ~~include~~August ~~approximately~~31, $42018,~~840~~ of1,001,533 ~~Property~~shares ~~Plant and Equipment net~~ of ~~accumulated~~Non-Voting ~~depreciation as~~Convertible ~~well~~Preferred asStock ~~all~~were ~~inventory~~issued ~~held~~and ~~at the McDonald Animal Hospital~~outstanding.

~~Assets disposed~~F-12 Table of ~~pursuant to the Agreement also include~~ Contents

~~(i) Essentially~~Common ~~all intellectual property, including computer software, utilized in connection with the operation of the McDonald Animal Hospital~~Shares

~~(ii) All~~The ~~telephone~~Company ~~numbers,~~is ~~fax~~authorized numbers, service marks, trademarks, trade names, fictitious business names, websites, business email addresses, vendor lists, promotional materials, vendor records and any and all business records including, but not limited to~~, such~~ ~~items~~issue ~~stored in computer memories~~500, ~~microfiche~~000,000 ~~paper~~shares ~~record~~of orCommon byStock ~~any~~at ~~other~~a ~~means~~par ~~relevant~~value ~~to the operation~~ of ~~the~~$0.0001 ~~McDonald Animal~~per ~~Hospital~~share.

~~(iii) All~~As ~~customer~~of ~~lists~~August 31, ~~customer contacts~~2019, and ~~any~~August ~~and~~31, ~~all~~2018, ~~customer~~49,171,083 ~~records~~shares ~~that~~of ~~are~~Common ~~related~~Stock towere ~~the~~issued ~~McDonald~~and ~~Animal Hospital~~outstanding.

~~As a~~NOTE ~~result~~5. ofDECONSOLIDATION ~~the~~OF ~~agreement,~~ZANDER ~~the Company recorded a non-cash pre-tax charge for the impairment of goodwill recorded in connection with the acquisition of the McDonald Animal Hospital of approximately $405~~THERAPEUTICS,~~000~~ ~~for the quarter ended November 30, 2012~~INC.

~~Pursuant to~~On ~~the~~May ~~Agreement~~5, ~~the~~2018, The Company isdeclared ~~obligated~~the todistribution ~~make~~on ~~payment~~a pro rata basis as a dividend in kind of ~~$13~~3,000,000 ~~within~~of ~~five~~the ~~days~~common shares of ~~the~~Zander ~~Closing~~Therapeutics, ofInc., ~~the~~par ~~Agreement~~value as$0.0001, ~~such term~~currently isowned ~~defined~~by inEntest ~~the~~Group, ~~Agreement~~Inc. to:

~~Pursuant to~~(a) ~~the~~Holders ~~Agreement,~~of ~~the~~record ~~Company~~of ~~agrees~~the tooutstanding ~~waive,~~common ~~release~~shares ~~and~~of ~~discharge~~the ~~McDonald~~Company ~~and~~as ~~Pet~~of ~~Pointer~~the ~~from~~record ~~all known and unknown claims~~date, ~~demands,~~ ~~causes~~which ofis ~~action,~~May ~~attorney's fees~~30, ~~costs, or expenses~~2018.

~~NOTE 11.~~(b) ~~DECONSOLIDATION~~Holders OFof ~~ZANDER~~record ~~THERAPEUTICS~~of the shares of any outstanding series of the preferred shares of the Company as of the record date, ~~INC~~which is May 30, 2018.

~~On May~~Shareholders 5,of ~~2018~~the Company shall receive one (1) share of common stock of Zander Therapeutics, ~~The~~Inc. ~~Company~~for ~~declared~~each 17 shares of the ~~distribution~~Company’s oncommon aand/or ~~pro~~preferred ~~rata~~stock ~~basis~~held as aof the record date for such dividend. inThe ~~kind~~distribution of the 3,000,000 ~~of the~~ common shares of Zander Therapeutics, Inc., ~~par~~to ~~value~~the ~~$0.0001,~~common ~~currently~~and ~~owned~~preferred byshareholders ~~Entest~~of ~~Group~~the Company occurred on June 11, ~~Inc.~~2018 ~~to:~~(“Distribution Date”).

(As a~~) Holders~~ result of ~~record~~the payment of the ~~outstanding~~abovementioned ~~common~~property ~~shares~~dividend, of the Company’s aspercentage of ownership of Zander fell below 50% resulting in the ~~record~~deconsolidation ~~date,~~of ~~which~~Zander isas ~~May~~of ~~30,~~the ~~2018~~Distribution Date. As of the Distributio

~~(b) Holders~~Date ofall ~~record~~assets ofand ~~the~~liabilities ~~shares~~attributable ofto ~~any~~Zander ~~outstanding~~were ~~series~~derecognized ofby the ~~preferred~~Company. ~~shares~~The Company recognized a $10,034 gain as a result of the ~~Company~~deconsolidation. The Property dividend may be deemed to have occurred with a related party as the recipients were shareholders of Entest, including the ~~record~~then ~~date~~Chairman and Chief Executive Officer of Entest and Regen Biopharma, Inc. which is ~~May~~was ~~30,~~a ~~2018~~company under common control with Entest.

22The Company’s remaining shares of Zander, which consisted of 5,000,000 shares of Zander’s Series M Preferred Stock (“Zander M Stock”) were accounted for under the Equity Method as of the Distribution Date until November 29, 2018. The Zander M Stock was carried a Fair Value and the carrying value was increased by the Company’s proportionate share of earnings of Zander and decreased by cash dividends paid by Zander as well as the Company’s proportionate share of losses of Zander up to the carrying value. As of August 31, 2018, the carrying value of the Zander M Stock was decreased by the Company’s proportionate share of the losses of Zander and was 0. As of August 31, 2018, Entest beneficially owned 34.82% of the share equity of Zander.

~~Shareholders of~~During the ~~Company~~quarter ~~shall~~ended ~~receive~~November ~~one~~30, ~~(1)~~2018, ~~common~~the ~~share~~Company divested itself of the Zander ~~Therapeutics,~~M ~~Inc.~~Stock ~~for~~as ~~each~~satisfaction 17of ~~common~~$179,318 ~~and/or~~of ~~preferred~~interest ~~shares~~accrued ofbut unpaid owed by the Company ~~held~~and as$9,270 of ~~the~~unearned ~~record~~rental ~~date.~~payments ~~The~~made ~~distribution~~to of the ~~3,000,000~~Company. ~~common~~As ~~shares~~the of Zander ~~Therapeutics,~~M ~~Inc.~~Stock tohad ~~the~~a ~~common and~~carrying ~~preferred~~value ~~shareholders~~ of $0, the Company ~~occurred~~recognized ona ~~June~~gain 11of $188,589 ~~2018~~on ~~("Distribution~~the ~~Date")~~disposition.

~~As a~~NOTE ~~result of the payment of the abovementioned property dividend, the Company’s percentage of ownership of Zander fell below 50% resulting in the deconsolidation of Zander as of the Distribution Date~~6. AsDISPOSITION ofOF ~~the~~ENTEST ~~Distribution Date all assets and liabilities attributable to Zander were derecognized by the Company. The Company recognized a $10~~BIOMEDICAL,~~034gain~~ ~~as a result of the deconsolidation~~INC. ~~The Property dividend may be deemed to have occurred with a related party as the recipients were shareholders of Entest~~, ~~including the~~A ~~Chairman~~CALIFORNIA ~~and Chief Executive Officer of Entest and Regen Biopharma, Inc. which is a company under common control with Entest.~~CORPORATION

~~The Company’s~~During ~~remaining~~the ~~share~~quarter ofended ~~Zander~~November 30, ~~which~~2018 ~~consists of 5,000,000 shares of Zander’s Series M Preferred Stock (“Zander M Stock”) is accounted for under~~ the ~~Equity~~Company ~~Method~~divested asitself of ~~the~~Entest ~~Distribution~~Biomedical, ~~Date~~Inc., ~~The Zander M Stock is carried~~ a ~~Fair~~California ~~Value~~ corporation and ~~the~~wholly ~~carrying~~owned ~~value~~subsidiary, isfor ~~increased~~consideration byconsisting ~~the Company’s proportionate share~~ of ~~earnings~~$2,000 ~~of Zander and decreased by cash dividends~~ paid by ~~Zander~~an asentity ~~well~~controlled asby the Company’s ~~proportionate~~then ~~share~~Chairman ofand ~~losses~~Chief ofExecutive ~~Zander~~Officer, upDavid toR. ~~the~~Koos, ~~carrying~~as ~~value~~full .consideration Asfor ofEntest ~~August 31,~~Biomedical ~~2018~~Inc. ~~the~~as ~~carrying~~well ~~value~~as ofany ~~the~~and ~~Zander~~all Mfurniture, ~~Stock~~fixtures ~~has~~and ~~been~~equipment ~~decreased~~owned by the Company’s ~~proportionate~~which ~~share~~has ofa ~~the~~carrying ~~losses~~ amount of ~~Zander and is~~ $0. ~~As of August 31, 2018 Entest beneficially owns 34.82% of the share equity of Zander.~~

~~5 million~~The ~~shares~~Company ofrecognized ~~Zander~~a ~~Series~~loss Mof ~~Preferred~~$947 ~~Stock~~on ~~received by~~ the ~~Company~~disposition based on ~~June~~the ~~15,~~difference ~~2017~~between ~~in consideration of services rendered has been valued by~~ the ~~Company~~Net asAssets of the ~~deconsolidation~~subsidiary ~~date~~and ~~utilizing~~ the ~~following~~Consideration ~~inputs:~~paid.

Fair Value of Intellectual Property		1,030
Cash derecognized in Divestiture	$	(63	)
prepaid Expenses		168,000
Accrued Rent Receivable Derecognized in Divestiture	$	(6,000	)
Accounts Payable		454,493
Liabilities Derecognized in Divestiture	$	3,116
Due from Entest		7,357
Consideration Received in Divestiture	$	2,000
Accrued Expenses		2,148
Loss Recognized in Divestiture	$	(947	)
Enterprise Value		633,028
Less: Total Debt		(463,998	)
Enterprise Value available to Shareholders		169,030
Per Share		0.012286

~~The Chairman~~F-13 ~~and~~Table ~~Chief Executive Officer~~ of ~~the Company and Zander is David R. Koos. Zander may be considered a related party of the Company.~~Contents

~~SUMMARY INFORMATION~~NOTE ~~FOR ZANDER THERAPEUTICS ,INC~~7. ~~FOR~~INCOME ~~THE FISCAL YEAR ENDED AUGUST 31, 2018~~ TAXES

Revenue	0
Operating Loss	(2,801,376	)
Net Loss	(2,780,288	)
Portion of Net Loss attributable to Entest	(968,188	)

The Company provides for income taxes under ASC 740, “Income Taxes.” Under the asset and liability method of ASC 740, deferred tax assets and liabilities are recorded based on the differences between the financial statement and tax basis of assets and liabilities and the tax rates in effect when these differences are expected to reverse. A valuation allowance is provided for certain deferred tax assets if it is more likely than not that the Company will not realize tax assets through future operations.

23The income tax provision for the years ended August 31, 2019 and 2018, consists of the following:

NOTE 12. COMMITMENTS AND CONTINGENCIES

	August 31,			August 31,
	2019			2018
Net income (loss)	$	191,618		$	(1,477,484	)
Effective tax rate		21	%		21	%
Income tax expense (benefit)		40,240			(310,272	)
Less: valuation allowance		(40,240	)		310,272
Income tax expense (benefit)	$	-		$	-

~~On November~~Net 1,deferred ~~2011,~~tax ~~the~~assets ~~Company~~consist ~~entered~~of ~~into~~the anfollowing ~~agreement~~components toas ~~lease approximately 2,320 square feet~~ of ~~office~~August ~~space beginning December 1~~31, ~~2011~~2019 ~~for~~and ~~a period of five years.~~2018:

Rent to be charged to the Company pursuant to the lease is as follows:

	August 31,			August 31,
	2019			2018
Net operating tax carryforwards	$	5,963		$	2,156,652
Valuation allowance		(5,963	)		(2,156,652	)
Net deferred tax asset	$	-		$	-

$2On December 22,~~996 per~~ ~~month~~2017, ~~for~~the United States enacted the ~~period~~Tax ~~beginning~~Cuts ~~December~~and 1Jobs Act (the “Act”) resulting in significant modifications to existing law including lowering the corporate tax rate from 34% to 21%. In addition to applying the new lower corporate tax rate in 2018 and thereafter to any taxable income we may have, ~~2011~~the legislation affects the way we can use and ~~ending~~carry ~~November~~forward 30net operating losses previously accumulated and results in a revaluation of deferred tax assets and liabilities recorded on our balance sheet. The Company has completed the accounting for the effects of the Act during the year ended August 31, ~~2012~~2019. Given that current deferred tax assets are offset by a full valuation allowance, these changes will have no impact on the balance sheet.

At August 31, 2019 and 2018, the Company had $328,~~116 per~~393 ~~month~~and ~~for~~$10,269,773 respectively of the ~~period~~U.S. net operating losses (the “U.S. NOLs”), which begin to expire beginning ~~December~~in 12029. NOLs generated in tax years prior to July 31, ~~2012~~2018, ~~and~~can ~~ending~~be ~~November~~carryforward 30for twenty years, ~~2013~~whereas NOLs generated after July 31, 2018 can be carryforward indefinitely.

~~$3,241 per~~The ~~month~~NOL ~~for~~carry forwards are subject to certain limitations due to the ~~period~~change ~~beginning~~in ~~December~~control of the Company pursuant to Internal Revenue Code Section 382. The Company experienced a change in control for tax purposes in November 2018 (see Note 1). Due to change of control, ~~2013~~the ~~and~~Company ~~ending~~will not be able to carryover approximately $10,050,000 of NOL generated before November 3027, ~~2014~~2018 to offset future income.

~~$3,371 per~~NOTE ~~month~~8 ~~for~~- ~~the~~SUBSEQUENT ~~period beginning December 1, 2014 and ending November 30, 2015~~EVENTS

~~$3,506 per~~The ~~month~~Company ~~for~~has evaluated subsequent events through the ~~period~~date ~~beginning~~which ~~December~~the 1financial statements were available to be issued. All subsequent events requiring recognition as of August 31, ~~2015~~2019 have been incorporated into these financial statements and ~~ending~~there ~~November~~are 30no subsequent events that require disclosure in accordance with FASB ASC Topic 855, ~~2016~~“Subsequent Events.”

~~On November~~F-14 ~~27,~~Table ~~2016~~of ~~the lease was extended until November 30, 2021~~Contents

~~Rent to~~ITEM be9. ~~charged~~CHANGES toIN ~~the~~AND ~~Company~~DISAGREEMENTS ~~pursuant~~WITH toACCOUNTANTS ~~the~~ON ~~extension~~ACCOUNTING isAND asFINANCIAL ~~follows:~~DISCLOSURE

$2On April 9,~~996 per~~ ~~month~~2019 ~~for~~(the “Effective Date”), Entest Group, Inc. (the ~~period~~“Company”) ~~beginning~~accepted ~~December~~the 1resignation of AMC Auditing, ~~2016~~LLC (“AMC”) the Company’s prior independent registered public accounting firm, effective immediately. The change occurred in connection with AMC’s merger with Prager Metis CPAs, LLC (“Prager”). On the Effective Date, the board of directors of the Company approved the resignation of AMC and ~~ending~~the ~~November~~appointment 30by the Company of Prager to serve as the Company’s independent registered public accounting firm effective April 8, ~~2017~~2019.

~~$3,116 per~~ITEM ~~month~~9A. ~~for~~CONTROLS ~~the~~AND ~~period beginning December 1, 2017 and ending November 30, 2018~~PROCEDURES

~~$3,241 per~~Evaluation ~~month~~of ~~for~~disclosure ~~the~~controls ~~period beginning December 1, 2018~~ and ~~ending November 30, 2019~~procedures

$3Pursuant to Rule 13a-15(b) under the Securities Exchange Act of 1934 (“Exchange Act”),~~371 per~~ ~~month~~our ~~for~~company carried out an evaluation, with the participation of our company’s management, including our company’s Chief Executive Officer (our principal executive officer and our principal financial and accounting officer), of the effectiveness of our company’s disclosure controls and procedures (as defined under Rule 13a-15(e) under the Exchange Act) as of the end of the period ~~beginning~~covered ~~December~~by 1this report. Based upon that evaluation, ~~2019~~our company’s CEO concluded that our company’s disclosure controls and ~~ending~~procedures ~~November~~are 30not effective to ensure that information required to be disclosed by our company in the reports that our company files or submits under the Exchange Act, ~~2020~~is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our company’s management, including our company’s CEO, as appropriate, to allow timely decisions regarding required disclosure, due to the material weaknesses identified below.

$3It should be noted that any system of controls,~~506 per~~ ~~month~~however ~~for~~well designed and operated, can provide only reasonable, and not absolute, assurance that the ~~period~~objectives ~~beginning~~of ~~December~~the 1system are met. In addition, ~~2020~~the design of any control system is based in part upon certain assumptions about the likelihood of future events. Because of these and ~~ending~~other ~~November~~inherent 30limitations of control systems, ~~2021~~there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions.

~~This property~~Report isof ~~utilized~~Management ason ~~office~~Internal ~~space.~~Control ~~The~~over ~~Company~~Financial ~~believes that the foregoing property is adequate to meet its current needs.~~Reporting

~~NOTE 13~~Management of our company is responsible for establishing and maintaining adequate internal control over financial reporting for our company. ~~INVESTMENT~~Our ~~SECURITIES~~internal control system was designed, in general, to provide reasonable assurance to our company’s management and board regarding the preparation and fair presentation of published financial statements, but because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

~~On February~~Management ~~28,~~conducted ~~2017~~an evaluation of the ~~Company~~effectiveness ~~purchased~~of ~~3,500,000~~our internal control over financial reporting based on the framework in Internal Control – Integrated Framework issued by the Committee of Sponsoring Organizations of the ~~Series~~Treadway Commission. A ~~Preferred~~material ~~shares~~weakness ofis ~~Regen~~a ~~Biopharma~~deficiency, ~~Inc.for~~or ~~consideration~~a ~~consisting~~ combination of $5deficiencies,~~000~~ ~~and~~in ~~500~~internal control over financial reporting,~~000~~ ~~shares~~such ofthat ~~the~~there ~~Company’~~is a reasonable possibility that a material misstatement to our company's ~~Series~~annual Bor ~~Preferred~~interim ~~stock~~financial statements will not be prevented or detected.

~~The Series~~In Athe ~~Preferred~~course ~~shares~~ of ~~Regen~~management's ~~Biopharma~~assessment, ~~Inc.~~management ~~described~~concluded ~~above~~that ~~constitute~~our ~~the~~internal ~~Company’s~~control ~~sole~~over ~~investment~~financial ~~securities~~reporting was not effective as of August 31, ~~2017~~2019. ~~The~~We ~~Company~~have ~~had~~identified nothe ~~investment~~following ~~securities~~material asweaknesses ofin ~~August~~internal ~~31,~~control ~~2018~~over financial reporting:

· Segregation of Duties – As a result of ~~August~~limited 31resources, ~~2017:~~we did not maintain proper segregation of incompatible duties, namely the lack of an audit committee, an understaffed financial and accounting function, and the need for additional personnel to prepare and analyze financial information in a timely manner and to allow review and on-going monitoring and enhancement of our controls. The effect of the lack of segregation of duties potentially affects multiple processes and procedures · Maintenance of Current Accounting Records – We may from time to time fail to maintain our records that in reasonable detail accurately and fairly reflect the transactions of our company.

	3,500,000		Series A Preferred shares of Regen Biopharma, Inc
	Basis		Fair Value	Total Unrealized Gains in Other Comprehensive Income	Net Unrealized Gain or (Loss) realized during the quarter ended August 31, 2017
$	$5,000	$	$190,050	$185,050	$53,550

Table of Contents

24We are in the continuous process of improving our internal control over financial reporting in an effort to eliminate these material weaknesses through improved supervision and training of our staff, but additional effort is needed to fully remedy these deficiencies. Management has engaged a Certified Public Accountant as a consultant to assist with the financial reporting process in an effort to mitigate some of the identified weaknesses. Our company is still in its development stage and intends on hiring the necessary staff to address the weaknesses once revenue has been realized.

~~NOTE 14~~This annual report does not include an attestation report of our company’s registered public accounting firm regarding internal control over financial reporting. ~~STOCKHOLDERS~~Management's ~~EQUITY~~report was not subject to attestation by our company's registered public accounting firm pursuant to temporary rules of the Securities and Exchange Commission that permit our company to provide only management's report in this annual report.

~~The stockholders'~~Changes ~~equity~~in ~~section~~Internal ofControl ~~the~~Over ~~Company~~Financial ~~contains the following classes of capital stock as of August 31, 2018:~~Reporting

~~Common Stock:~~There have been no changes in our internal controls over financial reporting that occurred during the year ended August 31, 2019 that have materially or are reasonably likely to materially affect, our internal controls over financial reporting.

$0ITEM 9B.~~0001 par~~ ~~value,~~OTHER ~~500,000,000 shares authorized and 49,170,472 shares issued and outstanding as of August 31, 2018.~~INFORMATION

~~Preferred Stock:~~Except as provided above, there is no information to be disclosed in a report on Form 8-K during the fourth quarter of the year covered by this Form 10-K that has not been previously filed with the Securities and Exchange Commission.

~~$0.0001 par~~10 ~~value~~Table ~~5,000,000 shares authorized~~ of ~~which:~~Contents

~~(a)~~PART 100,000 are authorized as Series AA Preferred Stock of which 634 shares are issued and outstanding as of August 31, 2018 and (b) 4,400,000 are authorized as Series B Preferred Stock of which 728,073 shares are issued and outstanding as of August 31, 2018 and (c) 300,000 are authorized as Series AAA Preferred Stock of which 534 shares are issued and outstanding as of August 31, 2018.III

~~Upon any~~ITEM liquidation, dissolution, or winding up of the Company, whether voluntary or involuntary (collectively, a “Liquidation”), before any distribution or payment shall be made to any of the holders of Common Stock or any other series of preferred stock, the holders of Series B Preferred Stock shall be entitled to receive out of the assets of the Company, whether such assets are capital, surplus or earnings, an amount equal to $0.10. ~~per share of Series B Preferred Stock (the “Liquidation Amount”) plus all declared and unpaid dividends thereon~~DIRECTORS, ~~for~~EXECUTIVE ~~each~~OFFICERS ~~share~~AND ofCORPORATE ~~Series B Preferred Stock held by them.~~GOVERNANCE

~~If, upon~~All ~~any~~directors ~~Liquidation, the assets~~ of ~~the~~our ~~Company~~company ~~shall~~hold beoffice ~~insufficient~~until ~~to pay~~ the ~~Liquidation~~next ~~Amount,~~annual ~~together~~meeting ~~with declared and unpaid dividends thereon, in full to all holders~~ of ~~Series B Preferred Stock, then~~ the ~~entire~~security ~~net assets of the Company shall be distributed among the~~ holders ofor ~~the~~until ~~Series~~their Bsuccessors ~~Preferred~~have ~~Stock,~~been ~~ratably~~elected inand ~~proportion~~qualified. toThe ~~the~~officers ~~full~~of ~~amounts~~our tocompany ~~which~~are ~~they~~appointed ~~would otherwise~~by beour ~~respectively~~board ~~entitled~~of directors and ~~such~~hold ~~distributions~~office ~~August~~until betheir ~~made~~death, inresignation ~~cash~~ or inremoval ~~property~~from ~~taken~~office. atOur ~~its~~directors ~~fair~~and ~~value~~executive ~~(as~~officers, ~~determined in~~their ~~good faith by the Board)~~ages, orpositions ~~both~~held, atand ~~the~~duration ~~election~~as ofsuch, ~~the~~are ~~Board..~~as follows:

Non Voting Convertible Preferred Stock having a $1.00 par value:

Name		Position Held with the Company		Age		Date First Elected or Appointed
Peiwen Yu		President, Chief Executive Officer and Director		49		November 15, 2018

~~3,000,000 shares~~Business ~~authorized of which 1,001,533 shares are issued and outstanding as of August 31 2018 .~~Experience

~~Non Voting~~The ~~Convertible~~following ~~Preferred~~is ~~Stock~~a ~~shall~~brief ~~convert~~account atof the ~~option~~education ofand ~~the~~business ~~holder~~experience ~~into~~during ~~shares~~at ofleast the ~~corporation’s~~past ~~common~~five ~~stock at~~years aof ~~conversion~~each ~~price~~director, ~~equal~~executive toofficer ~~the~~and ~~greater~~key employee of ~~$0.01~~our ~~per~~company, ~~share~~indicating orthe ~~seventy~~person’s ~~percent~~principal ~~(70%)~~occupation ofduring ~~the~~that ~~lowest~~period, ~~Closing~~and ~~Price for~~ the ~~five (5)~~name ~~trading~~and ~~days~~principal ~~immediately~~business ~~preceding~~of ~~written~~the ~~receipt~~organization byin ~~the~~which ~~corporation~~such ofoccupation ~~the~~and ~~holder’s~~employment ~~intent~~were tocarried ~~convert~~out.

~~“CLOSING PRICE"~~Peiwen ~~shall~~Yu ~~mean~~- ~~the~~President ~~closing~~and ~~bid~~Chief ~~price~~Executive ~~for~~Officer ~~the~~and ~~corporation’s common stock on the Principal Market on a Trading Day as reported by Bloomberg Finance L.P.~~Director

~~“PRINCIPAL MARKET"~~Mr. ~~shall~~Yu ~~mean~~has ~~the~~been ~~principal~~Chairman ~~trading~~of ~~exchange~~Guangdong orBokai ~~market~~Electric ~~for~~Industrial ~~the~~Co., ~~corporation~~Ltd. since March 2005. He also serves as Chairman of a number of private companies in China such as Lianjiang Bokai Wood Industry Co., Ltd. and Zhanjiang Bokai Tourism Development Co., Ltd. Mr. Yu earned a master’s ~~common~~degree ~~stock~~in Business Administration from SUN YA-SEN UNIVERSITY in 2003 and a Bachelor of Administration Degree from the same institution.

~~“TRADING DAY”~~Our ~~shall~~company ~~mean~~believes athat ~~day~~Mr. onYu’s ~~which~~professional background experience gives him the ~~Principal~~qualifications ~~Market~~and ~~shall~~skills benecessary ~~open~~to ~~for~~serve ~~business~~as a director and officer of our company.

~~NOTE 15.~~Term ~~STOCK~~of ~~TRANSACTIONS~~Office

~~On September~~Our 8,directors ~~2017~~are appointed for a one-year term to hold office until the ~~Company~~next ~~issued~~annual ~~2,500,000~~general ~~Common~~meeting ~~Shares~~of our stockholders or until removed from office in ~~connection~~accordance with aour ~~conversion~~bylaws. Our officers are appointed by our board of ~~25,000~~directors ~~Non~~and ~~Voting~~hold ~~Convertible Preferred~~office ~~Shares~~until removed by the board.

25All officers and directors listed above will remain in office until the next annual meeting of our stockholders, and until their successors have been duly elected and qualified. There are no agreements with respect to the election of Directors. We have not compensated our Directors for service on our Board of Directors, any committee thereof, or reimbursed for expenses incurred for attendance at meetings of our Board of Directors and/or any committee of our Board of Directors. Officers are appointed annually by our Board of Directors and each Executive Officer serves at the discretion of our Board of Directors. We do not have any standing committees. Our Board of Directors may in the future determine to pay Directors’ fees and reimburse Directors for expenses related to their activities.

~~NOTE 16.~~11 ~~SUBSEQUENT~~Table ~~EVENTS~~of Contents

~~On October~~Employment ~~2, 2018 Entest Group, Inc. (the “Company”) amended Article 4 of the Company’s Articles of Incorporation to be and read as follows:~~Agreements

~~4. Authorized~~There ~~Shares:~~are no written employment agreements with our officers and directors.

~~The aggregate~~Family number of shares, which the corporation shall have authority to issue, shall consist of 500,000,000 shares of Common Stock having a $.0001 par value, and 5,000,000 shares of Preferred Stock having a $.0001 par value and 3,000,000 shares of Non Voting Convertible Preferred Stock having a $1.00 par value.Relationships

~~Non Voting~~There ~~Convertible~~are ~~Preferred~~no ~~Stock~~family ~~shall~~relationships ~~convert~~between atany ~~the option~~ of ~~the~~our ~~holder~~directors, ~~into~~executive ~~shares~~officers ofand ~~the~~proposed ~~corporation’s~~directors ~~common stock at a conversion price equal to the greater of (i) $0.001 per share~~ or ~~(ii)~~executive ~~seventy percent (70%) of the lowest Closing Price for the five (5) trading days immediately preceding written receipt by the corporation of the holder’s intent to convert~~officers.

~~“CLOSING PRICE"~~Involvement ~~shall~~in ~~mean~~certain ~~the~~legal ~~closing bid price for the corporation’s common stock on the Principal Market on a Trading Day as reported by Bloomberg Finance L~~proceedings.P.

~~“PRINCIPAL MARKET"~~To ~~shall~~the ~~mean~~best ~~the~~of ~~principal~~our ~~trading~~knowledge, ~~exchange~~none of our directors or ~~market~~executive ~~for~~officers has, during the ~~corporation’s~~past ~~common~~ten ~~stock.~~years:

~~“TRADING DAY”~~1. ~~shall~~been ~~mean~~convicted in a ~~day~~criminal onproceeding or been subject to a pending criminal proceeding (excluding traffic violations and other minor offences); 2. had any bankruptcy petition filed by or against the business or property of the person, or of any partnership, corporation or business association of which he was a general partner or executive officer, either at the ~~Principal~~time ~~Market~~of ~~shall~~the bankruptcy filing or within two years prior to that time; 3. been subject to any order, judgment, or decree, not subsequently reversed, suspended or vacated, of any court of competent jurisdiction or federal or state authority, permanently or temporarily enjoining, barring, suspending or otherwise limiting, his involvement in any type of business, securities, futures, commodities, investment, banking, savings and loan, or insurance activities, or to be ~~open~~associated ~~for~~with persons engaged in any such activity; 4. been found by a court of competent jurisdiction in a civil action or by the SEC or the Commodity Futures Trading Commission to have violated a federal or state securities or commodities law, and the judgment has not been reversed, suspended, or vacated; 5. been the subject of, or a party to, any federal or state judicial or administrative order, judgment, decree, or finding, not subsequently reversed, suspended or vacated (not including any settlement of a civil proceeding among private litigants), relating to an alleged violation of any federal or state securities or commodities law or regulation, any law or regulation respecting financial institutions or insurance companies including, but not limited to, a temporary or permanent injunction, order of disgorgement or restitution, civil money penalty or temporary or permanent cease-and-desist order, or removal or prohibition order, or any law or regulation prohibiting mail or wire fraud or fraud in connection with any business entity; or 6. been the subject of, or a party to, any sanction or order, not subsequently reversed, suspended or vacated, of any self-regulatory organization (as defined in Section 3(a)(26) of the Exchange Act (15 U.S.C. 78c(a)(26)), any registered entity (as defined in Section 1(a)(29) of the Commodity Exchange Act (7 U.S.C. 1(a)(29)), or any equivalent exchange, association, entity or organization that has disciplinary authority over its members or persons associated with a member.

~~The Common~~12 ~~and/or~~Table ~~Preferred Stock~~ of the Company may be issued from time to time without prior approval by the stockholders. The Common and/or Preferred Stock may be issued for such consideration as may be fixed from time to time by the Board of Directors- The Board of Directors may issue such share of Common and/or Preferred Stock in one or more series, with such voting powers, designations, preferences and rights or qualifications, limitations or restrictions thereof as shall be stated in the resolution or resolutions.”Contents

~~On November~~Section 16~~, 2018 Entest terminated its lease on office space. The property has been assumed by BST Partners which is permitting the Company to utilize the space free of charge on~~ (a) ~~week~~Beneficial toOwnership ~~week~~Reporting ~~basis.~~Compliance

~~BST Partners~~Our common stock is ~~controlled~~not byregistered ~~David~~pursuant ~~Koos~~to Section 12 of the Securities Exchange Act of 1934, as amended (the ~~Company’s~~"Exchange ~~Chairman~~Act"). Accordingly, our executive officers and ~~Chief~~directors ~~Executive~~and ~~Officer~~persons who own more than 10% of a registered class of our equity securities are not subject to the beneficial ownership reporting requirements of Section 16(1) of the Exchange Act.

~~On November~~Code ~~16,~~of ~~2018 Zander Therapeutics Inc. and the Company agreed to terminate Zander’s sublease with the Company ( See Note 6) effective the rental period commencing November, 2018.~~Ethics

On November 1611, ~~2018~~2009 ~~Regen~~we ~~Biopharma~~adopted ~~Inc.~~a ~~and~~Code ~~the~~of ~~Company~~Ethics ~~agreed~~pursuant to ~~terminate~~Section ~~Regen’s~~406 ~~sublease~~of ~~with~~ the ~~Company~~Sarbanes-Oxley (Act ~~See~~of ~~Note 6)~~2002 ~~effective~~which ~~the~~was ~~rental~~filed ~~period~~as ~~commencing~~Exhibit 14.1 to our Annual Report on Form 10-K filed on November 17, ~~2018~~2009.

~~David R.~~Board ~~Koos serves as Chairman~~ and ~~Chief~~Committee ~~Executive Officer of the Company, Zander Therapeutics, Inc. and Regen Biopharma Inc.~~Meetings

~~On November~~Our 16board of directors held no formal meetings during the year ended August 31, ~~2018:~~2019. All proceedings of the board of directors were conducted by resolutions consented to in writing by all the directors and filed with the minutes of the proceedings of the directors. Such resolutions consented to in writing by the directors entitled to vote on that resolution at a meeting of the directors are, according to the Nevada General Corporate Law and our Bylaws, as valid and effective as if they had been passed at a meeting of the directors duly called and held.

~~Entest Group,~~Nomination Inc. and David R. Koos agreed to satisfy any and all unpaid interest resulting from accrued interest earned on Notes Payable to Koos by Entest from the beginning of time to November 30, 2018 by transferring to Koos 3,000,000 shares of the Series M Preferred stock of Zander Therapeutics, Inc. owned by the CompanyProcess

~~Entest Group,~~As ~~Inc.~~of ~~and~~August ~~Blackbriar~~31, ~~Partners~~2019, ~~(“BP)~~we ~~agreed~~did tonot ~~satisfy~~effect any ~~and~~material ~~all~~changes ~~unpaid~~to ~~interest~~the ~~resulting~~procedures ~~from~~by ~~accrued~~which ~~interest earned~~our onshareholders ~~Notes~~may ~~Payable~~recommend nominees to BPour byboard ~~Entest~~of ~~from~~directors. ~~the~~Our ~~beginning~~board of ~~time~~directors does not have a policy with regards to ~~November~~the ~~30,~~consideration ~~2018~~of any director candidates recommended by ~~transferring~~our shareholders. Our board of directors has determined that it is in the best position to BPevaluate ~~20,000~~our ~~shares~~company’s requirements as well as the qualifications of each candidate when the ~~Series~~board Mconsiders ~~Preferred~~a ~~stock~~nominee for a position on our board of ~~Zander~~directors. ~~Therapeutics~~If shareholders wish to recommend candidates directly to our board, ~~Inc.~~they ~~owned~~may do so by sending communications to the ~~Company.~~president BPof isour ~~controlled~~company byat ~~David~~the ~~Koos~~address on the ~~Company’s sole~~cover ~~officer~~of ~~and~~this ~~director~~annual report.

~~Entest Group,~~Audit Inc. and the Sherman Family Trust (“SFT”) agreed to satisfy any and all unpaid interest resulting from accrued interest earned on Notes Payable to SFT by Entest from the beginning of time to November 30, 2018 by transferring to SFT 612,500 shares of the Series M Preferred stock of Zander Therapeutics, Inc. owned by the Company.Committee

26Currently our audit committee consists of our entire board of directors. We do not have a standing audit committee as we currently have limited working capital and minimal revenues. Should we be able to raise sufficient funding to execute our business plan, we will form an audit, compensation committee and other applicable committees utilizing our directors’ expertise.

~~Entest Group,~~Audit ~~Inc.~~Committee ~~and~~Financial Dunhill Ross Partners (“DR”) agreed to satisfy any and all unpaid interest resulting from accrued interest earned on Notes Payable to DR by Entest from the beginning of time to November 30, 2018 by transferring to DR 12,500 shares of the Series M Preferred stock of Zander Therapeutics, Inc. owned by the Company.Expert

~~Entest Group,~~Currently ~~Inc.~~our ~~and~~audit ~~the~~committee ~~Bio~~consists ~~Technology~~of ~~Partners~~our ~~Business~~entire ~~Trust~~board ~~(“BPBT”)~~of ~~agreed~~directors. toWe ~~satisfy~~do ~~any~~not ~~and~~currently ~~all~~have ~~unpaid~~a ~~interest resulting~~director ~~from~~who ~~accrued~~is ~~interest~~qualified ~~earned on Notes Payable~~ to ~~BPBT~~act byas ~~Entest from~~ the ~~beginning~~head of ~~time to November 30, 2018 by transferring to BPBT 412,500 shares of~~ the ~~Series~~audit ~~M Preferred stock of Zander Therapeutics, Inc~~committee. ~~owned by the Company.~~

~~Entest Group,~~ITEM ~~Inc~~11. ~~and~~EXECUTIVE the Bio Matrix Scientific Group, Inc. (“BMSN”) agreed to satisfy any and all unpaid interest resulting from accrued interest earned on Notes Payable to BMSN by Entest from the beginning of time to November 30, 2018 by transferring to BMSN 5,000 shares of the Series M Preferred stock of Zander Therapeutics, Inc. owned by the Company. David R. Koos serves as Chairman and Chief Executive Officer of the Company and BMSN.COMPENSATION

~~Entest Group,~~The ~~Inc.~~particulars ~~and~~of ~~Bostonia Partners (“BSP”) agreed to satisfy any and all unpaid interest resulting from accrued interest earned on Notes Payable to BSP by Entest from~~ the ~~beginning~~compensation ofpaid ~~time~~ to ~~November 30, 2018 by transferring to BSP 212,500 shares of~~ the ~~Series~~following ~~M Preferred stock of Zander Therapeutics, Inc. owned by the Company.~~persons:

~~Entest Group,~~(a) ~~Inc.~~our ~~and~~principal ~~Regen~~executive ~~Biopharma~~officer; (b) each of our two most highly compensated executive officers who were serving as executive officers at the end of the years ended August 31, ~~Inc.~~2019 and 2018 and (~~“RGBP”~~c) ~~agreed~~up to ~~satisfy~~two ~~any~~additional ~~and~~individuals ~~all~~for ~~unpaid~~whom ~~interest~~disclosure ~~resulting~~would ~~from~~have ~~accrued interest~~been ~~earned~~provided onunder ~~Notes~~(b) ~~Payable~~but tofor ~~RGBP~~the byfact ~~Entest~~that ~~from~~the individual was not serving as our executive officer at the ~~beginning~~end of ~~time~~the toyears ~~November~~ended 30August 31, 2019 and 2018, bywho ~~transferring~~we will collectively refer to ~~RGBP~~as ~~250,000 shares~~the named executive officers of our company, are set out in the ~~Series~~following Msummary ~~Preferred~~compensation ~~stock~~table, ofexcept ~~Zander~~that ~~Therapeutics~~no disclosure is provided for any named executive officer, ~~Inc.~~other ~~owned~~than byour principal executive officers, whose total compensation did not exceed $100,000 for the ~~Company.~~respective fiscal year:

~~Entest Group,~~13 ~~Inc.~~Table ~~and Regen Biopharma, Inc. (“RGBP”) agreed to satisfy any and all rent prepaid by RGBP to Entest from the beginning~~ of ~~time to November 30, 2018 by transferring to RGBP 475,000 shares of the Series M Preferred stock of Zander Therapeutics, Inc. owned by the Company.~~Contents

David R. Koos serves as Chairman and Chief Executive Officer of the Company and RGBP.

SUMMARY COMPENSATION TABLE
Name and Principal Position	Year	Salary ($)			Bonus ($)		Stock Awards ($)		Option Awards ($)		Non-Equity Incentive Plan Compensa-tion ($)		Change in Pension Value and Nonqualified Deferred Compensa-tion Earnings ($)		All Other Compensa-tion ($)		Total ($)
Peiwen Yu⁽¹⁾	2019		-			-		-		-		-		-		-		-
President, CEO and Director	2018		N/A			N/A		N/A		N/A		N/A		N/A		N/A		N/A

David Koos⁽²⁾	2019		-			-		-		-		-		-		-		-
Former Chairman, President, Acting CFO, Secretary and Director	2018		120,000	(3)		17,000		-		-		-		-		-		137,000

___________

(1)	Mr. Yu was appointed president, CEO and a director on November 15, 2018.
(2)	Mr. Koos resigned all officer positions on November 15, 2018 and as a director on November 21, 2018.
(3)	Does not include $88,000 in salary accrued but unpaid during prior periods paid to David Koos during the fiscal year ended August 31, 2018.

~~Item 9.~~There ~~Changes~~are no arrangements or plans in ~~and~~which ~~Disagreements~~we ~~with~~provide ~~Accountants~~pension, onretirement ~~Accounting~~or similar benefits for directors or executive officers. Our directors and ~~Financial~~executive ~~Disclosure~~officers may receive share options at the discretion of our board of directors in the future. We do not have any material bonus or profit sharing plans pursuant to which cash or non-cash compensation is or may be paid to our directors or executive officers, except that share options may be granted at the discretion of our board of directors.

~~During the~~Grants Registrant's most two most recent fiscal years there were no disagreements with AMC Auditing (“AMC”) , the Company’s independent registered public accounting firm, whether or not resolved, on any matter of ~~accounting principles~~Plan-Based or practices, financial statement disclosure, or auditing scope or procedure, which, if not resolved to AMC’s satisfaction, would have caused it to make reference to the subject matter of the disagreement in connection with its report on the Registrant's financial statements.Awards

~~Item 9A.~~During ~~Controls~~the ~~and~~fiscal ~~Procedures~~year ended August 31, 2019 we did not grant any stock options.

~~a) Evaluation~~Option ofExercises ~~disclosure controls~~ and ~~procedures.~~Stock Vested

~~The principal~~During ~~executive~~our ~~officer~~fiscal ~~and~~year ~~principal~~ended ~~financial officer have evaluated the Company’s disclosure controls and procedures as of~~ August 31, ~~2018.~~2019 ~~Based~~there ~~on this evaluation, they have concluded that the disclosure controls and procedures~~ were ~~effective to~~no ~~ensure~~options ~~that~~exercised ~~the information required to be disclosed~~ by ~~the~~our ~~Company~~named in the reports that it files or submits under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported, within the time periods specified in the Commission’s rules and forms and to ensure that information required to be disclosed by the Company in the reports that it files or submits under the Securities Exchange Act of 1934 is accumulated and communicated to the Company’s management, including its principal executive and principal financial officers~~, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure~~. ~~David Koos is the Company’s CEO and acting CFO. He functions as the Company’s principal executive officer and principal financial officer.~~

~~b) Management’s~~Compensation ~~annual~~of ~~report on internal control over financial reporting.~~Directors

~~Management of~~We ~~the~~do ~~Company~~not ishave ~~responsible~~any agreements for ~~establishing~~compensating ~~and~~our ~~maintaining~~directors ~~adequate~~for ~~internal~~their ~~control~~services ~~over~~in ~~financial~~their ~~reporting~~capacity as ~~defined~~directors, ~~in Rule~~although ~~13a-15(f)~~such ~~promulgated~~directors ~~under~~are expected in the ~~Securities~~future ~~and~~to ~~Exchange~~receive ~~Act~~stock options to purchase shares of ~~1934.~~our ~~Rule~~common ~~13a-15(f)~~stock ~~defines~~as ~~internal~~awarded ~~control~~by ~~over~~our ~~financial reporting~~board asof ~~follows:~~directors.

~~“The term~~No ~~internal~~compensation ~~control~~was ~~over~~paid ~~financial~~to ~~reporting~~non-employee isdirectors ~~defined~~for ~~as a process designed by, or under~~ the ~~supervision~~year ~~of,~~ended ~~the~~August ~~issuer's principal executive and principal financial officers~~31, or persons performing similar functions, and effected by the issuer's board of directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles and includes those policies and procedures that:2019.

~~Pertain to~~14 ~~the~~Table ~~maintenance~~ of ~~records that in reasonable detail accurately and fairly reflect the transactions and dispositions of the assets of the issuer;~~Contents

~~Provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles~~Pension, ~~and~~Retirement ~~that~~or ~~receipts~~Similar ~~and~~Benefit ~~expenditures of the issuer are being made only in accordance with authorizations of management and directors of the issuer; and~~Plans

~~Provide reasonable~~There ~~assurance~~are ~~regarding~~no ~~prevention~~arrangements or ~~timely~~plans ~~detection~~in ofwhich ~~unauthorized~~we ~~acquisition~~provide pension, ~~use~~retirement or ~~disposition~~similar ofbenefits ~~the~~for ~~issuer's assets~~directors ~~that~~or ~~could~~executive officers. We have ano material ~~effect~~bonus onor profit sharing plans pursuant to which cash or non-cash compensation is or may be paid to our directors or executive officers, except that stock options may be granted at the ~~financial~~discretion ~~statements~~of the board of directors or a committee thereof.”

~~The Company’s~~Indebtedness ~~internal control over financial reporting is a process designed under the supervision~~ of ~~the~~Directors, ~~Company’s~~Senior ~~management to~~Officers, ~~provide~~Executive ~~reasonable~~Officers ~~assurance regarding the reliability of financial reporting~~ and ~~the~~Other ~~preparation of the Company’s financial statements for external purposes in accordance with U.S. generally accepted accounting principles.~~Management

~~In designing~~None ~~and~~of ~~evaluating~~ our ~~disclosure~~directors ~~controls~~or ~~and~~executive ~~procedures,~~officers or any associate or affiliate of our ~~management~~company ~~recognized~~during ~~that~~the ~~disclosure~~last ~~controls~~two ~~and~~fiscal ~~procedures~~years, no ~~matter~~is ~~how~~or ~~well~~has ~~conceived~~been ~~and~~indebted ~~operated,~~to ~~can~~our ~~provide~~company ~~only~~by away ~~reasonable~~of guarantee, ~~not~~support ~~absolute~~agreement, ~~assurance~~letter ~~that~~of ~~the~~credit ~~objectives~~or ofother ~~the~~similar ~~disclosure controls~~agreement ~~and~~or ~~procedures~~understanding ~~are~~currently ~~met~~outstanding.

~~The Company’s~~ITEM management assessed the effectiveness of its internal control over financial reporting as of August 31, 2018 based on the framework in 2013 Committee of Sponsoring Organizations of the Treadway Commission, or COSO, framework12. ~~Based.”~~SECURITY ~~Based on~~OWNERSHIP ~~its~~OF ~~assessment,~~CERTAIN ~~management~~BENEFICIAL ~~believes~~OWNERS ~~that,~~AND asMANAGEMENT ofAND ~~August~~RELATED ~~31,~~STOCKHOLDER ~~2018, the Company’s internal control over financial reporting is effective.~~MATTERS

28The following table sets forth, as of December 16, 2019, certain information with respect to the beneficial ownership of our common and preferred shares by each shareholder known by us to be the beneficial owner of more than 5% of our common and preferred shares, as well as by each of our current directors and executive officers as a group. Each person has sole voting and investment power with respect to the shares of common and preferred stock, except as otherwise indicated. Beneficial ownership consists of a direct interest in the shares of common and preferred stock, except as otherwise indicated.

~~Management's report~~Common was not subject to attestation by the Company's registered public accounting firm pursuant to temporary rules of the Securities and Exchange Commission that permit the company to provide only management's report in this annual report. This exemption for smaller reporting companies provided under the temporary rules referenced above has been made permanent under Section 989G of the Dodd-Frank Wall Street Reform and Consumer Protection Act.Stock

(c) There have been no changes during the quarter ended August 31, 2018 in the Company’s internal controls over financial reporting that have materially affected, or are reasonably likely to materially affect, internal control over financial reporting.

Name and Address of Beneficial Owner	Amount and Nature of Beneficial Ownership	Percentage of Class⁽¹⁾
Peiwen Yu c/o Entest Group, Inc.	23,733,334 Common / Direct	48.27%
*Directors and Executive Officers as a Group*	*23,733,334 Common*	*48.27%*
Life Sciences Journeys’ Inc. 1106 2^nd Street Encinitas CA 92024	2,500,000 Common / Direct	5.08%
*5% Shareholders as a Group*	*2,500,000 Common*	*5.08%*

~~Item 10. Directors, Executive Officers and Corporate Governance~~____________

~~On June~~(1) 19Under Rule 13d-3, ~~2009~~a ~~the~~beneficial ~~Board~~owner of ~~Directors~~a security includes any person who, directly or indirectly, through any contract, arrangement, understanding, relationship, or otherwise has or shares: (i) voting power, which includes the power to vote, or to direct the voting of shares; and (ii) investment power, which includes the ~~Company~~power ~~elected~~to ~~David~~dispose Ror direct the disposition of shares. ~~Koos~~Certain shares may be deemed to be beneficially owned by more than one person (if, a ~~director~~for ofexample, persons share the ~~Company~~power ~~and~~to ~~appointed~~vote Dror the power to dispose of the shares). ~~Koos President~~In addition, ~~Chief~~shares ~~Executive~~are ~~Officer,~~deemed ~~Secretary,~~to ~~Chief~~be ~~Financial~~beneficially ~~Officer~~owned by a person if the person has the right to acquire the shares (for example, ~~Principal~~upon ~~Accounting~~exercise ~~Officer~~of an option) within 60 days of the ~~Company.~~date Dras of which the information is provided. ~~Koos resigned~~In ascomputing ~~Chief~~the ~~Financial~~percentage ~~Officer~~ownership onof ~~March~~any 31person, ~~2010~~the ~~and~~amount ~~assumed~~of shares outstanding is deemed to include the ~~position~~amount of ~~Acting~~shares ~~Chief~~beneficially ~~Financial~~owned ~~Officer~~by such person (and ~~Principal Accounting~~only ~~Officer~~such onperson) ~~August~~by 8,reason ~~2011~~of ~~upon~~these acquisition rights. As a result, the ~~resignation~~percentage of ~~Tammy~~outstanding L.shares ~~Reynolds~~of ~~who~~any ~~served~~person as ~~Chief~~shown ~~Financial~~in ~~Officer~~this ~~from~~table does not necessarily reflect the ~~period~~ ~~from~~person’s ~~March~~actual ~~31,~~ownership ~~2010~~or voting power with respect to ~~August~~the 8number of shares of common stock actually outstanding on December 16, ~~2011~~2019. As of December 16, 2019 there were 49,171,083 shares of our company’s common stock issued and outstanding.

~~Education:~~15 Table of Contents

~~DBA -~~Series ~~Finance~~B ~~(December 2003)~~Preferred

Atlantic International University

Name and Address of Beneficial Owner	Amount and Nature of Beneficial Ownership	Percentage of Class
Tomas Ichim 9255 Town Center Dr San Diego CA 92121	500,000 Series B Preferred / Direct	68.6%
Thomas Donnelly 38 Miriam Road Denistone, NSW Australia	100,000 Series B Preferred / Direct	13.761%
Linda Black 521 Garfield Ave Winter Park FL 32789	100,000 Series B Preferred / Direct	13.761%
*5% Shareholders as a Group*	*700,000 Series B Preferred*	*96.12%*

~~Ph.D. - Sociology (September 2003)~~_________

~~Atlantic International~~(1) ~~University~~As of December 16, 2019 there were 728,073 Series B Preferred shares issued and outstanding.

~~MA -~~Series ~~Sociology~~AA ~~(June 1983)~~Preferred

University of California - Riverside, California

Name and Address

of Beneficial Owner

Amount and Nature of

Beneficial Ownership

Percentage

of Class

Peiwen Yu

c/o Entest Group, Inc.

667 Series AA Preferred / Direct

100.%

Directors and Executive Officers as a Group

667 Series AA Preferred

100%

~~Five Year Employment History:~~_________

Position:	Company Name:	Employment Dates:
Chairman, President, Chief Executive Officer, Secretary, Chief Financial Officer, Principal Account Officer	Entest Group, Inc	June 19, 2009 to the present
Chairman Chief Executive Officer, Secretary and Treasurer	Zander Therapeutics, Inc.	June 2015 to the Present
Chairman and CEO	Regen Biopharma, Inc.	April 24, 2012 to Present
Acting CFO	Regen Biopharma, Inc.	April 24, 2012 to February 11, 2015
President	Regen Biopharma, Inc.	May 29, 2013 to October 9, 2013
Chief Financial Officer, Principal Accounting Officer	Entest BioMedical, Inc	June 19, 2009 to March 31, 2010
Acting Chief Financial Officer, Principal Accounting Officer	Entest BioMedical, Inc	August 8, 2011 to the present
Chairman, President, CEO and Acting CFO	Bio-Matrix Scientific Group, Inc.	June 14, 2006 (Chairman) to Present; June 19, 2006 (President, CEO and Acting CFO); June 19, 2006 (Secretary) to Present

(1)	As of December 16, 2019 there were 667 Series AA Preferred shares issued and outstanding.

~~Code of~~Series ~~Ethics~~AAA Preferred

On November 11, 2009 we adopted a Code of Ethics pursuant to Section 406 of the Sarbanes-Oxley Act of 2002

Name and Address

of Beneficial Owner

Amount and Nature of

Beneficial Ownership

Percentage

of Class

Peiwen Yu

c/o Entest Group, Inc.

534 Series AAA Preferred / Direct

100.%

Directors and Executive Officers as a Group

534 Series AAA Preferred

100%

~~Director Independence~~_________

29(1) As of December 16, 2019 there were 534 Series AAA Preferred shares issued and outstanding.

~~Audit Committee~~Non-Voting ~~and~~Convertible ~~Audit Committee Financial Expert~~Preferred

The sole member of the Company’s board of Directors may not be considered independent as he is also its sole officer. The Company is not a "listed company" under Securities and Exchange Commission (“SEC”) rules and is therefore not required to have an audit committee comprised of independent directors. The Company does not currently have an audit committee, however, for certain purposes of the rules and regulations of the SEC and in accordance with the Sarbanes-Oxley Act of 2002, the Company’s Board of Directors is deemed to be its audit committee and as such functions as an audit committee and performs some of the same functions as an audit committee including: (1) selection and oversight of our independent accountant; (2) establishing procedures for the receipt, retention and treatment of complaints regarding accounting, internal controls and auditing matters; and (3) engaging outside advisors. The Board of Directors has determined that its member is able to read and understand fundamental financial statements and has substantial business experience that results in that member's financial sophistication. Accordingly, the Board of Directors believes that its member has the sufficient knowledge and experience necessary to fulfill the duties and obligations that an audit committee would have.

Name and Address

of Beneficial Owner

Amount and Nature of

Beneficial Ownership

Percentage

of Class

Peiwen Yu

c/o Entest Group, Inc.

1,001,533 Non-Voting Convertible Preferred / Direct

100.%

Directors and Executive Officers as a Group

1,001,533 Non-Voting Convertible Preferred

100%

~~Nominating and Compensation Committees~~_________

~~The Company~~(1) ~~does not~~As ~~have~~of ~~standing~~December ~~nominating or compensation committees~~16, or2019 ~~committees~~there ~~performing~~were ~~similar~~1,001,533 ~~functions.~~Non-Voting ~~The board of~~Convertible ~~directors~~Preferred ~~believes~~shares ~~that~~issued it is not necessary to have a compensation committee at this time because the functions of such committee are adequately performed by the board of directors. The board of directors also is of the view that it is appropriate for the Company not to have a standing nominating committee because the board of directors has performed and ~~will perform adequately the functions of a nominating committee~~outstanding. ~~The Company is not a "listed company" under SEC rules and is therefore not required to have a compensation committee or a nominating committee.~~

~~Shareholder Communications~~16 Table of Contents

~~There has~~Changes not been any defined policy or procedure requirements for stockholders to submit recommendations or nomination for directors. There are no specific, minimum qualifications that the board of directors believes must be met by a candidate recommended by the board of directors. Currently, the entire board of directors decides on nominees, on the recommendation of any member of the board of directors followed by the board’s review of the candidates’ resumes and interview of candidates. Based on the information gathered, the board of directors then makes a decision on whether to recommend the candidates as nominees for director. The Company does not pay any fee to any third party or parties to identify or evaluate or assist in ~~identifying or evaluating potential nominee.~~Control

~~Because management and~~We ~~the~~are ~~Board~~unaware of ~~Directors of~~any ~~the~~contract ~~Company are~~or ~~the~~other ~~same~~arrangement ~~people,~~or provisions of our Articles or Bylaws the ~~Board~~operation of ~~Directors~~which ~~has~~may ~~determined~~at ~~not~~a tosubsequent ~~adopt a~~date ~~formal~~result ~~methodology~~in ~~for~~a ~~communications~~change ~~from~~of ~~shareholders~~control onof ~~the~~our ~~belief~~company. ~~that~~There are not any ~~communication~~provisions ~~would~~in beour ~~brought~~Articles toor Bylaws, the ~~Board~~operation of ~~Directors’~~ ~~attention~~which bywould ~~virtue~~delay, ofdefer, ~~the~~or ~~co-extensive~~prevent ~~capacities~~a ofchange ~~the~~in ~~Board~~control of ~~Directors~~our company.

~~SUMMARY COMPENSATION~~Except ~~TABLE~~as disclosed herein, no director, executive officer, shareholder holding at least 5% of shares of our common stock, or any family member thereof, had any material interest, direct or indirect, in any transaction, or proposed transaction since the year ended August 31, 2019, in which the amount involved in the transaction exceeded or exceeds the lesser of $120,000 or one percent of the average of our total assets at the year-end for the last three completed fiscal years:

Name and Principal Position	Year		Salary ($)			Bonus ($)		Stock Awards ($)		Restricted Stock Awards ($)		Option Awards ($)		Non Equity Incentive Plan Compensation ($)		Nonqualified Deferred Compensation Earnings ($)		All Other Compensation ($)		Total ($)
David Koos Chairman, President and CEO		From September 1, 2017 to August 31, 2018	$	120,000	*		17,000	$			0		0		0		0		0	$137,000
		From September 1, 2016 to August 31, 2017	$	120,000	**		0		50		0		0		0		0		0	$120,050

On July 3, 2018, Zander entered into a sublease agreement with Entest whereby Zander would sublet office space located at 4700 Spring Street, Suite 304, La Mesa, California 91942 from Entest on a month to month basis for $6,000 per month beginning July 5, 2018. On November 16, 2018 Zander Therapeutics Inc. and the Company agreed to terminate Zander’s sublease with the Company effective the rental period commencing November 2018. David R. Koos, who served as Chairman and Chief Executive Officer of Zander as of that date also served as Chairman and Chief Executive Officer of Entest as of that date. Zander was under common control with Entest as of that date.

*Does notOn ~~include~~November ~~$88~~16,~~000~~ in2018, ~~salary~~Entest ~~accrued~~Group, ~~but~~Inc. and its then Chairman and Chief Executive Officer, David R. Koos, agreed to satisfy any and all unpaid ~~during~~interest ~~prior~~resulting ~~periods~~from ~~paid~~accrued interest earned on Notes Payable to Koos by Entest from the beginning of time to November 30, 2018 by transferring to David R. Koos ~~during~~3,000,000 shares of the ~~fiscal~~Series ~~year~~M ~~ended~~Preferred ~~August~~stock 31of Zander Therapeutics, ~~2018~~ Inc. owned by the Company.

** DoesEntest ~~not~~Group, ~~include~~Inc. ~~$102,000~~and inBlackbriar ~~salary~~Partners ~~accrued~~(“BP”) ~~but~~agreed to satisfy any and all unpaid ~~during~~interest ~~prior~~resulting ~~periods~~from ~~paid~~accrued interest earned on Notes Payable to BP by Entest from the Company’s inception to November 30, 2018 by transferring to BP 20,000 shares of the Series M Preferred stock of Zander Therapeutics, Inc. owned by the Company. BP is controlled by David Koos, ~~during~~as of that date, the ~~fiscal~~Company’s ~~year~~then ~~ended~~Chairman ~~August 31,~~and ~~2017~~Chief Executive Officer.

Entest Group, Inc. and the Bio Matrix Scientific Group, Inc. (“BMSN”) agreed to satisfy any and all unpaid interest resulting from accrued interest earned on Notes Payable to BMSN by Entest from the Company’s inception to November 30, 2018 by transferring to BMSN 5,000 shares of the Series M Preferred stock of Zander Therapeutics, Inc. owned by the Company. As of November 16, 2018, David R. Koos was the Chairman and Chief Executive Officer of the Company and BMSN.

~~Item 12~~Entest Group, Inc. ~~Security~~and ~~Ownership~~Regen ofBiopharma, ~~Certain~~Inc. ~~Beneficial~~(“RGBP”) ~~Owners~~agreed ~~and~~to ~~Management~~satisfy any and ~~Related~~all ~~Stockholder~~unpaid ~~Matters~~interest resulting from accrued interest earned on Notes Payable to RGBP by Entest from the beginning of time to November 30, 2018 by transferring to RGBP 250,000 shares of the Series M Preferred stock of Zander Therapeutics, Inc. owned by the Company.

~~The following~~Entest ~~table~~Group, ~~sets~~Inc. ~~forth~~and ~~information~~Regen ~~known~~Biopharma, toInc. ~~the~~(“RGBP”) ~~Company~~agreed ~~with~~to ~~respect~~satisfy toany ~~the~~and ~~beneficial~~all ~~ownership~~rent ofprepaid ~~each~~by ~~class~~RGBP ofto ~~the~~Entest ~~Company’s capital~~from ~~stock~~the asbeginning of time to November 1530, 2018 ~~for (1) each person known~~ by ~~the~~transferring ~~Company~~ to ~~beneficially~~RGBP ~~own~~475,000 ~~more~~shares ~~than 5%~~ of ~~each class of~~ the ~~Company’s~~Series ~~voting~~M ~~securities,~~Preferred ~~(2) each~~stock ~~executive officer, (3) each~~ of ~~the~~Zander ~~Company’s~~Therapeutics, ~~directors~~Inc. ~~and (4) all~~owned ofby the Company~~’s executive officers and directors as a group~~. As of November 1516, 2018 ~~Entest BioMedical~~, ~~Inc~~David R. ~~had~~ ~~49,170,472~~Koos ~~common~~was ~~shares~~the ~~outstanding,~~Chairman ~~728, 073 Series B Preferred shares outstanding , 667 Series AA preferred shares outstanding, 534 Series AAA preferred shares outstanding,~~ and ~~1001533~~Chief ~~shares~~Executive Officer of the Company’s ~~Non~~and ~~Voting Convertible Preferred Stock outstanding~~RGBP.

~~Based on~~In 49November 2018,~~170~~ the Company divested itself of Entest BioMedical,~~472~~ ~~shares~~Inc., ~~issued~~a ~~and~~California ~~outstanding~~corporation, asfor ofconsideration ~~November~~consisting 15of $2,~~2018~~ 000 paid by an entity controlled by David R. Koos.

Title of Class		Name and Address of Beneficial Owner	Amount and Nature of Beneficial Owner		Percent of Class
	Common	David R. Koos* C/o Entest Group, Inc., Inc 4700 SPRING STREET, SUITE 203, LA MESA, CALIFORNIA, 91942		23,300,001		47.39	%
	Common	Life Sciences Journeys, Inc. 1106 2nd street Encinitas, CA ,92024		2,500,000		5.08	%
	Common	All Officers and Directors As a Group		23,300,001		47.39	%

The Company recognized a loss of $947 on the disposition based on the difference between the Net Assets of the subsidiary and the consideration paid.

*Includes 66During the year ended August 31,~~667~~ ~~common~~2019, ~~shares~~the ~~owned~~Company’s bysole ~~Bio-Matrix~~officer ~~Scientific~~advanced ~~Group,~~to ~~Inc.~~the ~~(David~~Company ~~Koos~~an isamount ~~CEO~~of $21,197 ~~President~~for ~~and~~the ~~Chairman~~payment of ~~Bio-Matrix~~operating ~~Scientific Group,~~expenses ~~Inc~~on behalf of the Company.). ~~Includes~~As 8of August 31,~~000~~ 2019,~~000~~ ~~common~~and ~~shares~~2018, ~~owned~~the byCompany ~~Regen~~was ~~Biopharma~~obligated to the officer, ~~Inc.~~for ~~(David~~an ~~Koos~~unsecured, isnon-interest ~~CEO~~bearing ~~and~~demand ~~Chairman~~loan with a balance of ~~Regen~~$21,197 ~~Biopharma~~and $0, ~~Inc~~ respectively.)

~~Based on~~17 ~~728,009~~Table ~~shares issued and outstanding as~~ of ~~November~~ ~~15, 2018.~~Contents

Title of Class	Name and Address of Beneficial Owner	Amount and Nature of Beneficial Owner		Percent of Class
Series B Preferred	David R. Koos* C/o Entest Group, Inc 4700 SPRING STREET, SUITE 203, LA MESA, CALIFORNIA, 91942		15,001		2.6	%
Series B Preferred	Thomas Ichim 9255 Town Center Dr San Diego, CA,92121		500,000		68.6	%
Series B Preferred	Thomas Donnelly 38 Miriam Road Denistone, NSW Australia		100,000		13.761	%
Series B Preferred	Linda Black 521 Garfield Ave Winter Park, FL 32789		100,000		13.761	%
Series B Preferred	All Officers and Directors as a Group*		15,001		2.6	%

Director Independence

*Includes 8We currently act with one director,~~334~~ ~~Series~~Peiwen BYu. ~~Preferred shares~~We ~~owned~~have bydetermined ~~Bio-Matrix~~that ~~Scientific~~we ~~Group~~do not have an independent director, ~~Inc.~~as ~~(David~~that ~~Koos~~term is ~~CEO,~~used ~~President~~in ~~and~~Rule ~~Chairman~~4200(a)(15) of ~~Bio-Matrix~~ ~~Scientific~~the ~~Group,~~Rules ~~Inc~~of National Association of Securities Dealers.).

31Currently our audit committee consists of our entire board of directors. We currently do not have nominating, compensation committees or committees performing similar functions. There has not been any defined policy or procedure requirements for shareholders to submit recommendations or nomination for directors.

~~Based on~~From ~~667~~inception ~~shares~~to ~~issued~~present date, we believe that the members of our audit committee and ~~outstanding~~the asboard of ~~November~~ ~~15,~~directors ~~2018~~ have been and are collectively capable of analyzing and evaluating our financial statements and understanding internal controls and procedures for financial reporting.

Title of Class	Name and Address of Beneficial Owner	Amount and Nature of Beneficial Owner		Percent of Class
Series AA Preferred Shares	David R. Koos C/o Entest Group, Inc 4700 SPRING STREET, SUITE 203, LA MESA, CALIFORNIA, 91942		667		100	%
Series AA Preferred Shares	All Officers and Directors As a Group		667		100	%

ITEM 14. PRINCIPAL ACCOUNTING FEES AND SERVICES

~~Based on~~The ~~534~~aggregate ~~shares~~fees ~~issued~~billed for the most recently completed fiscal year ended August 31, 2019 and ~~outstanding~~for asfiscal ~~of November~~year 15ended August 31, 2018 for professional services rendered by the principal accountant for the audit of our annual financial statements and review of the financial statements included in our quarterly reports on Form 10-Q and services that are normally provided by the accountant in connection with statutory and regulatory filings or engagements for these fiscal periods were as follows:

Title of Class	Name and Address of Beneficial Owner		Amount and Nature of Beneficial Owner				Percent of Class
Fee Category	Year Ended August 31, 2019				Year Ended August 31, 2018
Series AAA Preferred Shares	David R. Koos C/o Entest Bio Medical Inc., Inc 4700 SPRING STREET, SUITE 203, LA MESA, CALIFORNIA, 91942			534				100	%
Audit Fees	$	8,500			$	15,000
Series AAA Preferred Shares	All Officers and Directors As a Group			534				100	%
Audit-Related Fees		8,000				13,546
Tax Fees		-				-
All Other Fees		-				-
Total Fees	$	16,500			$	28,546

~~Based on~~Audit ~~1,001,533~~Fees: ~~shares~~Aggregate ~~issued~~fees ~~and~~billed ~~outstanding~~for asprofessional services rendered for the audit of ~~November~~ ~~15,~~the ~~2018~~ Company's annual financial statements.

Title of Class	Name and Address of Beneficial Owner	Amount and Nature of Beneficial Owner		Percent of Class
Non Voting Convertible Preferred	Bio Technology Partners Business Trust 8130 Las Mesa Blvd Las Mesa CA 91941		124,000		12.38	%
Non Voting Convertible Preferred	David R. Koos C/o Entest Bio Medical Inc., Inc 4700 SPRING STREET, SUITE 203, LA MESA, CALIFORNIA, 91942*		185,852		18.55	%
Non Voting Convertible Preferred	Bostonia Partners 1204 Tangerine El Cajon, CA,92021		327681		32.7	%
Non Voting Convertible Preferred	Dunhill Ross Partners La Mesa CA		165,000		16.4	%
Non Voting Convertible Preferred	Sherman Family Trust La Mesa, CA		199,000		19.8	%
Non Voting Convertible Preferred	All Officers and Directors as a Group*		185,852		18.55	%

Audit Related Fees: Aggregate fees billed for professional services rendered for assurance and related services that were reasonably related to the performance of the audit or review of our financial statements and are not reported under “Audit Fees” above. During the year ended August 31, 2019 these fees were primarily derived from review of financial statements in the Company's Form 10Q Reports.

* IncludesAll ~~185,852~~services ~~shares~~listed ~~owned~~were pre-approved by ~~Regen~~the ~~Biopharma,~~Board ~~Inc.~~of ~~David~~Directors, R.functioning ~~Koos~~as isthe ~~Chairman~~Audit ~~and~~Committee ~~Chief~~in ~~Executive~~accordance ~~Officer~~with ofSection ~~both~~2(a) ~~Entest~~3 ~~Biomedical, Inc.~~of ~~and~~the ~~Regen~~Sarbanes-Oxley ~~Biopharma,~~Act ~~Inc~~of 2002.

32Our board of directors has considered the nature and amount of fees billed by our independent auditors and believes that the provision of services for activities unrelated to the audit is compatible with maintaining our independent auditors’ independence.

~~Item 13.~~18 ~~Certain~~Table ~~Relationships~~of ~~and Related Transactions, and Director Independence~~Contents

~~As of~~PART August 31, 2018 the Company remains indebted to David R. Koos , the Company’s sole officer and director, in the principal amount of $2,600 due and payable in whole or in part at the demand of David Koos and bearing simple interest at a rate of 15% per annum.IV

~~As of~~ITEM ~~August~~15. 31EXHIBITS, ~~2018~~FINANCIAL ~~the~~STATEMENT Company remains indebted to Blackbriar Partners in the principal amount of $11,600 of which $1,000 is due and payable February 17, 2018 and bears simple interest at a rate of 10%per annum and of which $7,000 is due and payable February 28, 2018 and bears simple interest at a rate of 10% per annum , of which$3,000 is due and payable May 4, 2019 and bears simple interest at a rate of 10% per annum and of which $600 is due and payable August 20, 2019 and bears simple interest at a rate of 10% per annum.SCHEDULES

~~Blackbriar Partners~~(a) isFinancial ~~controlled by David R. Koos , the Company’s sole officer and director.~~Statements

As of August 31, 2018 the Company remains indebted to Regen Biopharma, Inc. in the principal amount of $4,551 due and payable in whole or in part at the demand of the holder and bearing simple interest at a rate of 10% per annum. David R. Koos , the Company’s sole officer, serves as Chairman and Chief Executive officer of Regen Biopharma, Inc.

	(1)	Financial statements for our company are listed in the index under Item 8 of this document.

	(2)	All financial statement schedules are omitted because they are not applicable, not material or the required information is shown in the financial statements or notes thereto.

~~On October~~(b) 1, 2014 Regen Biopharma Inc. entered into an agreement to sublease approximately 2,320 square feet of office space from the Company. Entest Biomedical Inc. is under common control with Regen Biopharma, Inc. as the Chairman and CEO of the Company also serves as the Chairman and CEO of Regen Biopharma, Inc. The sublease is on a month to month basis and rent payable to the Company by Regen Biopharma Inc is equal to the rent payable to the lessor by the Company and is to be paid in at such time specified in accordance with the original lease agreement between the Company and the lessor. On January 20, 2015 the sublease was amended retroactive to January 1, 2015 as follows:Exhibits

The rent payable to Entest BioMedical, Inc. by the subtenant is equal to Five Thousand Dollars per month ($5,000) and is to be paid in at such time specified in accordance with the original lease agreement between the Entest BioMedical, Inc. (“Entest”) and the lessor. All charges for utilities connected with premises which are to be paid under the master lease shall be paid by Regen Biopharma, Inc. for the term of this sublease to the extent that such charges exceed the difference between the rent payable to the lessor by Entest under the master lease and the rent payable to Entest by Regen Biopharma, Inc.

Exhibit Number		Description
(31)		Rule 13a-14 (d)/15d-14d) Certifications
31.1*		Section 302 Certification by the Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer
(32)		Section 1350 Certifications
32.1**		Section 906 Certification by the Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer
101**		Interactive Data File
101.INS		XBRL Instance Document
101.SCH		XBRL Taxonomy Extension Schema Document
101.CAL		XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF		XBRL Taxonomy Extension Definition Linkbase Document
101.LAB		XBRL Taxonomy Extension Label Linkbase Document
101.PRE		XBRL Taxonomy Extension Presentation Linkbase Document

On February 28, 2016, the Company purchased from a third party 3,500,000 shares of the Series A Preferred stock of Regen Biopharma, Inc for consideration consisting of $5,000 cash and 500,000 shares of the Company’s Series B Preferred Stock. On July 3, 2018 the Company sold the aforementioned 3,500,000 shares to Zander for consideration consisting of $35,000. David R. Koos, who serves as Chairman and Chief Executive Officer of Zander also serves as Chairman and Chief Executive Officer of Entest. Zander is under common control with Entest.____________

~~On July~~* 3,Filed 2018 Zander entered into a sublease agreement with Entest whereby Zander would sublet office space located at 4700 Spring Street, Suite 304, La Mesa, California 91942 from Entest on a month to month basis for $6,000 per month beginning July 5, 2018herewith.

~~David R.~~** ~~Koos,~~Furnished ~~who serves as Chairman and Chief Executive Officer of Zander also serves as Chairman and Chief Executive Officer of Entest. Zander is under common control with Entest.~~herewith

~~On November~~ITEM 16~~, 2018 Entest terminated its lease on office space~~. ~~The~~FORM ~~property~~10-K ~~has been assumed by BST Partners which is permitting the Company to utilize the space free of charge on a week to week basis.~~SUMMARY

~~BST Partners is controlled by David Koos, the Company’s Chairman and Chief Executive Officer~~None.

3319 Table of Contents

~~On November 16, 2018 Zander Therapeutics Inc. and the Company agreed to terminate Zander’s sublease with the Company effective the rental period commencing November, 2018.~~SIGNATURES

~~On November~~Pursuant ~~16,~~to ~~2018~~the ~~Regen~~requirements ~~Biopharma~~of ~~Inc.~~Section ~~and~~13 ~~the~~or ~~Company~~15(d) ~~agreed~~of tothe ~~terminate~~Securities ~~Regen’s~~Exchange ~~sublease~~Act ~~with~~of 1934, the ~~Company~~registrant ~~effective~~has ~~the rental~~duly ~~period~~caused ~~commencing~~this ~~November~~report to be signed on its behalf by the undersigned, ~~2018~~thereto duly authorized.

David R. Koos serves as Chairman and Chief Executive Officer of the Company, Zander Therapeutics, Inc. and Regen Biopharma Inc.

	ENTEST GROUP, INC.

Dated December 19, 2019	By:	/s/ Peiwen Yu
		Peiwen Yu
		President, Chief Executive Officer and Director
		(Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer)

~~On November~~Pursuant 16to the requirements of the Securities Exchange Act of 1934, ~~2018:~~this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

Entest Group, Inc. and David R. Koos agreed to satisfy any and all unpaid interest resulting from accrued interest earned on Notes Payable to Koos by Entest from the beginning of time to November 30, 2018 by transferring to Koos 3,000,000 shares of the Series M Preferred stock of Zander Therapeutics, Inc. owned by the Company.

Dated: December 19, 2019		/s/ Peiwen Yu
		Peiwen Yu
		President, Chief Executive Officer and Director
		(Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer)

Entest Group, Inc. and Blackbriar Partners (“BP) agreed to satisfy any and all unpaid interest resulting from accrued interest earned on Notes Payable to BP by Entest from the beginning of time to November 30, 2018 by transferring to BP 20~~,000 shares of the Series M Preferred stock of Zander Therapeutics, Inc. owned by the Company. BP is controlled by David Koos the Company’s sole officer and director.~~

Entest Group, Inc. and the Bio Matrix Scientific Group, Inc. (“BMSN”) agreed to satisfy any and all unpaid interest resulting from accrued interest earned on Notes Payable to BMSN by Entest from the beginning of time to November 30, 2018 by transferring to BMSN 5,000 shares of the Series M Preferred stock of Zander Therapeutics, Inc. owned by the Company. David R. Koos serves as Chairman and Chief Executive Officer of the Company and BMSN.

Entest Group, Inc. and Regen Biopharma, Inc. (“RGBP”) agreed to satisfy any and all unpaid interest resulting from accrued interest earned on Notes Payable to RGBP by Entest from the beginning of time to November 30, 2018 by transferring to RGBP 250,000 shares of the Series M Preferred stock of Zander Therapeutics, Inc. owned by the Company.

Entest Group, Inc. and Regen Biopharma, Inc. (“RGBP”) agreed to satisfy any and all rent prepaid by RGBP to Entest from the beginning of time to November 30, 2018 by transferring to RGBP 475,000 shares of the Series M Preferred stock of Zander Therapeutics, Inc. owned by the Company.

David R. Koos serves as Chairman and Chief Executive Officer of the Company and RGBP.

Director Independence

Audit Committee and Audit Committee Financial Expert

The Company’s sole director may not be considered independent as he is also an officer. The Company is not a "listed company" under Securities and Exchange Commission (“SEC”) rules and is therefore not required to have an audit committee comprised of independent directors. The Company does not currently have an audit committee, however, for certain purposes of the rules and regulations of the SEC and in accordance with the Sarbanes-Oxley Act of 2002, the Company’s Board of Directors is deemed to be its audit committee and as such functions as an audit committee and performs some of the same functions as an audit committee including: (1) selection and oversight of our independent accountant; (2) establishing procedures for the receipt, retention and treatment of complaints regarding accounting, internal controls and auditing matters; and (3) engaging outside advisors. The Board of Directors has determined that its sole member is able to read and understand fundamental financial statements and has substantial business experience that results in the member's financial sophistication. Accordingly, the Board of Directors believes that its member has the sufficient knowledge and experience necessary to fulfill the duties and obligations that an audit committee would have.

Nominating and Compensation Committees

The Company does not have standing nominating or compensation committees, or committees performing similar functions. The Board of Directors believes that it is not necessary to have a compensation committee at this time because the functions of such committee are adequately performed by the board of directors. The Board of Directors also is of the view that it is appropriate for the Company not to have a standing nominating committee because the Board of Directors has performed and will perform adequately the functions of a nominating committee. The Company is not a "listed company" under SEC rules and is therefore not required to have a compensation committee or a nominating committee.

Shareholder Communications

There has not been any defined policy or procedure requirements for stockholders to submit recommendations or nomination for directors. There are no specific, minimum qualifications that the board of directors believes must be met by a candidate recommended by the board of directors. Currently, the entire board of directors decides on nominees, on the recommendation of any member of the board of directors followed by the board’s review of the candidates’ resumes and interview of candidates. Based on the information gathered, the board of directors then makes a decision on whether to recommend the candidates as nominees for director. The Company does not pay any fee to any third party or parties to identify or evaluate or assist in identifying or evaluating potential nominee.

The Board of Directors has determined not to adopt a formal methodology for communications from shareholders on the belief that any communication would be brought to the board of directors’ attention by virtue of communication with management.

Item 14. Principal Accounting Fees and Services

The following table sets forth the aggregate fees billed to us by AMC Auditing during the period beginning September 1, 2017 and ending August 31, 2018:

Audit Fees	$	15,000
Audit Related Fees		13,546
Tax Fees		0
All Other Fees		0
	$	28,546

Audit Fees: Aggregate fees billed for professional services rendered for the audit of the Company's annual financial statements.

Audit Related Fees: Aggregate fees billed for professional services rendered for assurance and related services that were reasonably related to the performance of the audit or review of our financial statements and are not reported under “Audit Fees” above. During the year ended August 31, 2017 these fees were primarily derived from review of financial statements in the Company's Form 10Q Reports.

All services listed were pre-approved by the Board of Directors, functioning as the Audit Committee in accordance with Section 2(a) 3 of the Sarbanes-Oxley Act of 2002.

The Board has considered whether the services described above are compatible with maintaining the independent accountant's independence and has determined that such services have not adversely affected the independence of AMC Auditing.

Item 15. Exhibit Index

31.1	CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE SARBANESE-OXLEY ACT OF 2002
31.2	CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO SECTION 302 OF THE SARBANESE-OXLEY ACT OF 2002
32.1	CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. SECTION 1350 AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
32.2	CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350 AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
3(i)		TEXT OF CERTIFICATE OF AMENDMENT Name Change( (a) )
10.1		Stock Purchase Agreement (b)
3(ii)		TEXT OF CERTIFICATE OF AMENDMENT ART. 4(c)
99.1		Stock purchase Agreement sale of control shares (d)

(a) Incorporated by reference to Exhibit 3(i) of the Company’s Form 8-K dated 1/10/2018

(b) Incorporated by reference to Exhibit 10.1 of the Company’s Form 8-K dated 7/5/2018

(d) Incorporated by reference to Exhibit 10.1 of the Company’s Form 8-K filed 11/20/2018

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

			Entest BioMedical, Inc.
		By:	/s/David R. Koos
			Name: David R. Koos
			Title: President, Chairman, Chief Executive Officer
			Date: November 21, 2018.

Pursuant to the requirements of the Securities Exchange Act of 1934, this Report has been signed below by the following persons on behalf of the Registrant and in the capacities indicated on November 25, 2014.

		By:	/s/ David R. Koos
			Name: David R. Koos
			Title: President, Chairman of the Board of Directors, Chief Executive Officer, Acting Chief Financial Officer
			Date: November 21, 2018.

Filing Compare · ENTEST GROUP, INC.